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ABSTRACT 
 
 
 Viruses such as influenza suppress host immune function by a variety of methods. 
This may result in a significant morbidity through several pathways, including facilitation 
of secondary bacterial pneumonia from pathogens such as Streptococcus pneumoniae. 
Lung-resident alveolar macrophages (AMs) act as the first line of innate cellular 
immunity against respiratory bacterial pathogens, including pneumococcus. Therefore, 
they represent an attractive target for study. 
 
 Before investigating the impact of influenza infection on resident AMs, we first 
characterized different subsets of lung-resident macrophages in naïve mice using a novel 
in vivo labeling approach in conjunction with multicolor flow cytometric analysis and 
confocal microscopic examination. A stable fluorescent dye, PKH26-PCL, was 
administered intranasally to selectively label the lung-resident macrophages in a well-
established murine model prior to influenza infection. We determined the turnover 
kinetics of the lung-resident macrophage subsets during the course of influenza infection. 
More than 90% of resident AMs were lost in the first week after influenza, while the 
remaining cells had a necrotic phenotype. 
 
 To establish the impact of this innate immune defect, influenza-infected mice 
were challenged with a small dose of Streptococcus pneumoniae. Early AM-mediated 
bacterial clearance was significantly impaired during the AM depletion phase in 
influenza-infected mice – about 50% of the initial bacterial inoculum could be harvested 
from the alveolar airspaces 3 hours later. In mock-infected mice, by contrast, more than 
95% of inocula up-to-50-fold higher was efficiently cleared. Co-infection during the AM 
depletion phase caused significant body weight loss and mortality. Two weeks after 
influenza, the AM population was fully replenished with successful re-establishment of 
the early innate host protection. Local GM-CSF treatment induced partial expansion of 
resident AMs during influenza infection. Thus, it led to partial restoring of the impaired 
early bacterial clearance with efficient protection against secondary pneumococcal 
pneumonia. 
 
 We conclude that a novel immunosuppression mechanism occurs during influenza 
infection through the resident AM depletion. Among other potential effects, this 
establishes a niche for secondary pneumococcal infection by altering early cellular innate 
immunity in the lungs resulting in pneumococcal outgrowth and lethal pneumonia. This 
novel mechanism will inform development of novel therapeutic approaches to restore 
lung innate immunity against bacterial super-infections. 
 
 Secondary bacterial pneumonia (SBP) is a leading cause of the increased 
hospitalizations and mortality during influenza epidemics and pandemics despite routine 
use of standard antibiotics. Antibiotic-induced immunopathology associated with 
bacterial cell wall lysis has been suggested to contribute to these poor outcomes. Using 
Streptococcus pneumoniae in a well-established murine model of SBP following 
influenza, we stratified disease severity based on the pneumococcal load in the lungs via 
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in vivo bioluminescence imaging. Ampicillin treatment cured mice with mild pneumonia 
but was ineffective against severely pneumonic mice, despite effective bacterial killing. 
This treatment failure makes it crucial to explore immunmodulation approaches that can 
prevent the aggravated lung immunopathology during antibiotic treatment of severe SBP. 
 
 Therefore, we tested the efficacy of the standard anti-inflammatory drug 
dexamethasone as an adjunctive corticosteroid therapy. Adjunctive dexamethasone 
treatment significantly improved ampicillin-induced immunopathology and survival 
outcomes in mice with severe SBP. However, early dexamethasone therapy during 
primary influenza infection impaired the adaptive immunity in the lungs as manifest by 
increased viral titers, with an associated loss of its protective functions in SBP. The 
clinical use of corticosteroids as an adjunctive therapy for treating pneumonia is still 
under debate. However, our findings support adjunctive clinical use of corticosteroids in 
severe cases of community-acquired pneumonia. Nonetheless, dexamethasone treatment 
has drawbacks implied by delayed body weight recovery in dexamethasone-treated mice, 
which may explain the published controversy on the corticosteroid efficacy in terms of 
disease morbidity. This relative success of our animal model of SBP to simulate the 
clinical therapeutic settings in humans will help explore novel immunomodulation 
approaches to improve the poor outcomes of antibiotic treatment of severe community-
acquired pneumonia. 
 viii 
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CHAPTER 1.    INTRODUCTION 
 
 
Influenza Viruses 
 
 
Classification and Ecology 
 
 Influenza viruses are members of the Orthomyxoviridae family. They encompass 
a wide variety of strains that cause significant respiratory infections in humans and 
various animals. Influenza viruses are antigenically classified into three genera: A, B, and 
C. Influenza A viruses can be further subtyped based on their two surface glycoproteins 
antigens: hemagglutinin (HA) and neuraminidase (NA) [1]. So far, 16 HA subtypes and 9 
NA subtypes have been identified [2, 3]. Standard nomenclature of influenza viruses 
includes virus genus, species from which it was isolated (if non-human), location where it 
was isolated, isolate number, and isolate year. HA and NA subtypes are added for 
influenza A viruses [4]. An example nomenclature of an influenza virus commonly used 
in the laboratory is influenza virus A/Puerto Rico/8/34 (H1N1). 
 
 The primary reservoir for influenza A viruses is aquatic birds. However, they can 
infect several hosts including pigs, horses, whales, seals, minks and humans. The 
reported ability of interspecies transmission of influenza A viruses is a major source for 
new pandemic strains with serious consequences on public and veterinary health [5-8]. 
 
 
Structure of Influenza A Viruses 
 
 Influenza A viruses are defined as enveloped RNA viruses. The viral capsid is 
surrounded by a lipid bilayer envelope acquired from the host cell membrane during viral 
particle release. The influenza A viral genome consists of 8 segmented, negative, single-
stranded RNA genes. These genes encode for up to 11 known proteins, due to two splice 
variants of non-structural (NS) and matrix (M) genes, in addition to a product of an 
alternate open reading frame of polymerase basic 1 gene (PB1) in some influenza A virus 
strains, known as PB1-F2 [9]. Influenza viral proteins have different functions and spatial 
positions. Three of them are integral in the lipid envelope – HA and NA are embedded in 
the envelop as the major surface glycoprotein spikes, while a splice variant of M gene 
called matrix protein (M2) forms ion channels traversing the envelope [10]. This studded 
envelop overlays a coat composed of another matrix protein (M1). These outer layers 
enclose the viral core containing non-structural protein 2 (NS2) and the ribonucleoprotein 
complex (RNP), which consists of viral RNA segmented genes coated with nucleoprotein 
(NP) and RNA-dependent RNA polymerase. The viral RNA polymerase is composed of 
3 subunits: 2 polymerase basic subunits (PB1 and PB2) and 1 polymerase acidic subunit 
(PA) (Figure 1-1) [4, 11]. Recently, a novel viral protein, termed PA-X, was identified as 
the product of the second open reading frame of PA gene which can be accessed through 
ribosomal frameshifting [12]. 
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Figure ‎1-1. Influenza A virus structure 
 
Reprinted with permission from Dr. Ian M. Mackay. Virology Down Under, 
http://www.uq.edu.au/vdu/ (Last accessed on September 5, 2013) [11]. 
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Replication Cycle 
 
 The influenza A virus replication cycle starts by virus attachment through HA 
spikes on the viral envelope to terminal N-acetylneuraminic (sialic) acid moieties on the 
host cell surface. The type of linkage of these terminal sialic acid moieties to galactose 
determines viral tropism to host cells, as HA may have preferential binding to sialic acid 
receptors with either α-2,3 or α-2,6 linkages [13]. Generally, HA of human influenza 
viruses binds preferentially to sialic acid with α-2,6 linkage, which is more abundant on 
human tracheal epithelial cells [14, 15], whereas HA of avian influenza viruses binds to 
sialic acid with α-2,3 linkage [13, 16, 17], which is abundant on gut and respiratory 
epithelial cells of ducks [18]. 
 
 Upon HA binding to the host cell sialic acid residues, receptor-mediated 
endocytosis occurs. The virus enters the host cell in a clathrin-coated endosome, whose 
acidic pH triggers a conformational change of HA leading to fusion of the viral and 
endosomal membranes, followed by release of nucleocapsid into the cell cytoplasm [19]. 
In addition, M2 channels in the viral envelope pump hydrogen protons into the viral core. 
This internal acidification process disrupts internal protein-protein interactions, causing 
the M1 protein to dissociate from RNP and eventually leading to viral uncoating and 
release of viral RNP into the cell cytoplasm [4, 20]. 
 
 After their cytosol release, viral RNPs are actively translocated to the host cell 
nucleus through nuclear localization signals on internal viral proteins [21]. Upon entering 
the nucleus, transcription and replication processes of the viral genome start. Viral RNA 
serves as a template for mRNA and complementary positive-stranded RNA (cRNA) 
synthesis. Next, viral mRNA is exported out of the nucleus to be translated into viral 
proteins. cRNA is amplified into genomic viral RNAs, which associate with internal viral 
proteins, forming newly synthesized viral RNP segments. Nuclear export of the progeny 
viral RNP segments into the cytoplasm is mediated by M1 and nuclear export protein 
(NEP)/NS2 proteins [4, 21]. Then, they are transported to the cell membrane – the site of 
viral RNP segments packaging and assembling of the new viral particles. Growing 
evidence suggests that the packaging process of eight unique viral RNP segments is a 
selective, yet unclear, process [22, 23]. M1 protein is accumulated at the cytoplasmic side 
of the lipid bilayer which facilitates viral budding. Finally, NA protein through its 
sialidase activity cleaves terminal sialic acid residues on both the host cell surface and the 
viral envelope to facilitate the release of new viral particles, and prevent aggregation of 
viral particles, respectively [4, 24]. 
 
 
Pathogenesis in Humans 
 
 Influenza and pneumonia remain among the leading causes of deaths worldwide. 
Influenza A viruses can cause acute respiratory viral infections that can be easily 
transmitted among humans by inhalation of respiratory droplets. They have been 
circulating since at least the 16th century with a unique ability to cause recurrent annual 
epidemics [25]. Moreover, upon emergence of a novel influenza virus, by which the total 
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population has not been attacked before and consequently people have no specific 
adaptive immunity against, this novel virus spreads quickly among different age groups 
and healthy young individuals of the population with rapid transmission to several 
regions worldwide leading to influenza pandemics. Several such pandemics occurred in 
the 20th century causing millions of deaths worldwide. The specter of influenza 
pandemics still imposes a continuous threat to world public health in the 21st century, 
after the recent swine H1N1 influenza pandemic emerged in 2009-2010 and caused more 
than 284,000 deaths globally in the first year [26, 27]. 
 
 In humans, acute influenza infections cause diseases of variable severity, ranging 
from mild upper respiratory tract infections to acute respiratory distress syndrome and 
death. Several factors count for the variability in infection outcomes. Therefore, it is 
crucial to understand factors related to the virus and the host which contribute to 
increased morbidity and mortality. 
 
 
Viral Virulence 
 
 Viral virulence is a complex phenomenon which involves several factors, 
including viral tropism, transmissibility, and replication efficiency [28]. It is a multigenic 
trait, resulting from the collective contribution of different viral genes and proteins into 
viral pathogenicity. However, certain viral genes from some highly virulent influenza 
strains may increase virulence if put into the genetic background of another strain. For 
example, studies of recombinant strains produced by a reverse genetics system using HA 
and NA genes or even a single HA gene from the highly virulent 1918 pandemic 
influenza strain plus the genetic background of another strain increased the recombinant 
virus virulence in mice [26, 29, 30]. Strikingly, just one mutation in a certain gene of 
some strains may greatly affect their virulence [26]. 
 
 Circulating highly virulent influenza viruses pose a continuous threat of a new 
serious influenza pandemic. An example of recently emerged highly pathogenic influenza 
strains that have pandemic potential is the avian H5N1 influenza viruses, which caused 
high fatality rate of about 60% in the identified infected humans [31]. However, they 
have poor human-to-human transmission and remain endemic in poultry populations, 
mostly in Southeast Asia [6]. Nonetheless, recent studies showed that these highly 
pathogenic viruses may naturally adapt and acquire efficient human-to-human 
transmission, posing a great threat to humans [32, 33]. With currently limited spread 
among humans, these highly pathogenic avian viruses have given only minor contribution 
to global influenza-associated morbidity and fatality with 378 deaths among cumulative 
637 cases of infection from 2003 until August 2013 [34]. 
 
 In general, it has been observed that influenza viral infections alone do not 
account for most mortality during seasonal, epidemic, or pandemic influenza periods. 
Instead, complications during influenza infections were found as the main reasons for 
increased influenza-associated mortality. For instance, people with certain comorbidities 
are considered high-risk populations during influenza epidemics and pandemics, and 
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antiviral therapy is highly recommended for them. This high-risk category includes those 
with weakened immunity, such as infants and children less than 5 years old, as well as the 
elderly, pregnant women, and people with serious respiratory or cardiovascular diseases. 
Additionally, bacterial super-infections remain a serious complication among all 
influenza-infected hosts and were found to complicate many severe cases of influenza 
infections and significantly contribute to fatalities during influenza epidemics and 
pandemics [35, 36]. 
 
 Despite its importance, viral virulence is primarily a threat to immunologically 
naïve hosts. Therefore, highly pathogenic viruses may only have minor effects on healthy 
individuals with previous exposure or those who were vaccinated against closely related 
viral strains. Thus, host immunity is another key factor in virus-host interactions and 
influenza infection outcomes. 
 
 
Host Immune Responses 
 
 Host immunity can be classified into two branches: innate non-specific immunity 
and adaptive specific immunity. Once the influenza virus enters its target cell and starts 
replication in the respiratory tract, diverse host immune responses launch, starting with 
initial responses of infected cells and progressing to more advanced and specific immune 
responses. To initiate host immune responses, a pathogen or its associated pathogenic 
activity must be detected. Detection is performed by receptors in the host cells called 
pattern recognition receptors (PRRs). These receptors play key roles in the innate 
immune response to infections by a wide range of microorganisms, including influenza 
viruses. PRRs are activated when they detect and bind to certain conserved microbe-
specific motifs or molecules, known as pathogen-associated molecular patterns (PAMPs). 
PPRs can also detect certain host endogenous molecules released during tissue damage 
called damage-associated molecular patterns (DAMPs). PRRs are composed of diverse 
sets of receptors including Toll-like receptors (TLRs), nucleotide oligomerization domain 
(NOD)-like receptors (NLRs), retinoic acid inducible gene-I (RIG-I)-like receptors 
(RLRs), and cytosolic DNA and viral RNA sensors. Some of them are expressed on the 
surface of host cells, including TLR1, TLR2, TLR4, TLR5, and TLR6, making them 
suitable for detecting extracellular pathogens and certain DAMPs. However, other PRRs, 
such as TLR3, TLR7, and TLR9, and RLRs, present intracellularly in the endosomes or 
host cell cytosol to detect intracellular pathogens [37, 38]. 
 
 Activation of various PRRs during influenza virus replication triggers certain 
signaling pathways in the detecting host cells, eventually leading to synthesis of different 
cytokines and chemokines (Figure 1-2) [28]. Infected respiratory epithelial cells and 
pulmonary macrophages are the first cells to detect viral replication. Three main 
categories of PRRs can detect influenza virus infection: TLRs, such as TLR3 and TLR7, 
which bind to viral double-stranded RNA and single-stranded RNA, respectively; RIG-I 
receptors which recognize newly synthesized viral RNAs [39]; and NLR receptor family 
pyrin domain containing 3 (NLRP3), which is activated by influenza viral RNA or M2 
ion channel activity during influenza infection [40-42]. Some of the cytokines produced 
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Figure ‎1-2. Molecular basis of immune responses at site of influenza infection 
 
Reprinted with permission from Elsevier. Salomon R, Webster RG. The influenza virus 
enigma. Cell 2009; 136:402-10 [28]. 
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early have strong antiviral activities, such as type I interferons (IFNα/β) and type III IFN 
(IFNλ), which protect nearby non-infected cells against influenza infection by inducing 
synthesis of various antiviral proteins. In addition, they stimulate dendritic cells to 
enhance antigen presentation for T cells, thereby facilitating adaptive immune response 
development. Inflammatory response may be blocked in the first 2 days after influenza 
infection but then pro-inflammatory cytokines and chemokines are suddenly released 
signaling recruitment and activation of various circulating immune cells to the site of 
infection (Figure 1-2) [43-45]. 
 
 Several types of host immune cells are recruited to the infection site with different 
kinetics and different performance characteristics but temporally integrated functions. 
Extravasation of innate immune cells, such as neutrophils, natural killer cells, exudate 
monocytes and macrophages, and dendritic cells start in the first few days after infection. 
Then, activated influenza-specific adaptive immune cells are recruited with more targeted 
functions in fighting influenza virus infection. After viral clearance, these influenza-
specific adaptive immune cells play a critical protective role against future re-infections 
by the same or closely related strains by establishing influenza-specific memory 
immunity (Figure 1-3) [46]. 
 
 Because of their spatial position on the mucosal surface of alveolar epithelium, 
resident alveolar macrophages (AMs) are the first innate immune cells to encounter 
influenza virus upon its spread to the lower respiratory tract. They detect early virus 
replication and become activated, releasing several pro-inflammatory cytokines and 
chemokines. Thereby, they signal recruitment of innate immune cells that participate in 
controlling viral replication during the inflammatory phase of infection. Different 
influenza A virus strains have different abilities to infect human and murine AMs [47]. 
However, infected AMs produce low virus yield. AMs were thought for a long time to be 
a central activator for the induced inflammatory cytokine storm when they are infected by 
the highly pathogenic H5N1 influenza viruses [43]. In contrast, a recent study strikingly 
showed that human AMs, and not blood monocyte-derived macrophages, can release 
only small amounts of pro-inflammatory cytokines after being infected by different 
influenza viruses, including highly pathogenic H5N1 viruses [48]. These data are 
relatively relevant with the observed immunosuppressive nature of AMs [49, 50]. In 
contrast, another study showed that influenza infections of isolated human AMs induce 
robust release of different cytokines and chemokines, including type I IFN, while 
downregulating expression of certain receptors, such as, macrophage scavenger receptor 
1 and CD36 [51]. 
 
 Dendritic cells (DCs) are generally professional antigen-presenting cells (APCs) 
that bridge innate and adaptive immunity. Their activation during influenza infection 
enhances the uptake, processing, and presentation of influenza antigens. Thereafter, some 
DCs migrate to the draining lymph nodes (DLNs) where they present influenza antigenic 
epitopes on either major histocompatibility complex (MHC) class I and II molecules to 
CD8
+
 T cells and CD4
+
 helper T (Th) cells, respectively. This step is crucial for the 
initiation of adaptive immune responses. In mouse models of influenza infection, several 
subsets of DCs, such as migratory CD103
+
 CD11b
-
 conventional DCs and CD11b
+
 DCs, 
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Figure ‎1-3. Kinetics of adaptive immune responses during primary and 
secondary influenza infections 
 
Reprinted with permission from Elsevier. Subbarao K, Murphy BR, Fauci AS. 
Development of effective vaccines against pandemic influenza. Immunity 2006; 24:5-9 
[46]. 
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have been identified to be crucial for mounting efficient adaptive immunity against 
influenza viruses. They carry influenza antigens from the site of infection and migrate to 
the DLNs to prime and activate expansion of influenza-specific T cells. In addition, 
monocyte-derived DCs may be necessary to sustain effector T cells in the lungs for viral 
clearance [52]. In contrast, some inflammatory DCs may also cause detrimental 
immunopathology in the lungs during lethal influenza infection [53-55]. 
 
 Natural killer (NK) cells are also important innate immune effector cells. They 
can directly kill influenza-infected cells after triggering their cytotoxicity receptors, such 
as NKp44 and NKp46, by binding to influenza HA proteins expressed on influenza-
infected cells. In addition, antibody-dependent cellular cytotoxicity (ADCC) is another 
mechanism in which NK cells lyse antibody-bound influenza-infected cells after binding 
their CD16 receptor (FcγRIII) to the Fc portion of the bound antibodies [43, 56]. 
 
 Neutrophil influx is a hallmark of the early innate immune response to influenza 
infection. Neutrophils significantly participate in limiting influenza viral replication in 
the early inflammatory phase of infection. Furthermore, they may also facilitate the 
initiation of adaptive immune responses. They release different cytokines and 
chemokines that signal recruitment and activation of DCs. In addition, they may 
modulate the activities of T cells [57-59]. On the other hand, if neutrophil influx and their 
pro-inflammatory functions are not tightly controlled, they may remarkably contribute to 
lung immunopathology and increased morbidity and lethality [60, 61]. 
 
 Exudate monocytes and macrophages also participate in the inflammatory innate 
immune response to influenza infection. Their infiltration is induced by different pro-
inflammatory cytokines and chemokines released from infected cells and virus-detecting 
immune cells, such as pulmonary macrophages and DCs. This process is mainly CCR2-
dependent preferentially recruiting CCR2
+
 mononuclear phagocytes. They contribute in 
limiting viral spread via phagocytosis of infected apoptotic bodies. However, they may 
also become destructive causing immunopathology by enhancing the release of pro-
inflammatory cytokines and tissue-damaging species, such as tumor necrosis factor-α, 
interleukin-6 (IL-6), and nitric oxide [54]. Thus, prophylactic CCR2-antagonist treatment 
significantly attenuated lung immunopathology without affecting viral clearance and 
improved survival in a mouse model of severe influenza infection [62]. 
 
 A few days after launching the acute inflammatory innate immune response, the 
influenza infection becomes more efficiently controlled by influenza-specific B cells and 
CD8
+
 T cells, both effectors of antibody-mediated (humoral) and cell-mediated (cellular) 
adaptive immunity (Figure 1-3 and Figure 1-4). They are initially activated in the 
secondary lymphatic tissues, such as the DLNs, after recognizing influenza antigenic 
epitopes presented on MHC class I and II molecules on the surface of activated APCs 
expressing co-stimulatory molecules with the help of activated CD4
+
 Th cells. After 
activation and clonal expansion, influenza-specific B cells and T cells migrate to an 
influenza infection site under chemoattractant gradient. Specific T cell receptors on the 
surface of CD8
+
 cytotoxic T cells recognize influenza antigenic epitopes presented on 
MHC class I molecules on influenza-infected host cells. They kill infected cells via 
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Figure ‎1-4. Adaptive immune response against influenza virus infection 
 
Adapted with permission from Nature Publishing Group. Subbarao K, Joseph T. 
Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev 
Immunol 2007; 7:267-78 [63]. 
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perforin-mediated cytolysis and granzymes and FAS/FASL-induced apoptosis. In 
addition, plasma cells secrete antibodies targeting several influenza antigenic epitopes, 
especially surface antigens HA, NA, and M2, which neutralize the infectivity of influenza 
viral particles (Figure 1-4). Furthermore, influenza-specific antibodies bound to viral 
particles facilitate their clearance and phagocytosis by binding to Fc receptors of various 
phagocytes. They also bind to influenza antigens expressed on the surface of infected 
cells and activate their killing by the NK cell ADCC mechanism [43]. 
 
 After viral clearance, some virus-specific B cells and T cells differentiate into 
memory cells. They reside mainly in some lymphoid organs and structures, such as the 
spleen and inducible bronchus-associated lymphoid tissue, establishing specific memory. 
Their protective functions rely on their ability to launch faster specific adaptive immune 
responses against future infections by the same or closely related influenza virus strains 
(Figure 1-3). 
 
 Indeed, efficient innate and adaptive host immune responses are required to 
inhibit viral replication and facilitate viral clearance. On the other hand, excessive 
immune responses will have deleterious effects and cause collateral lung tissue damage. 
Therefore, respiratory epithelial cells and other effectors play important roles to restore 
lung homeostasis during influenza infections and to prevent the damaging effects of 
robust host immune responses. For example, lung epithelial cells are highly expressing 
inhibitory molecule CD200 which inhibits inflammatory activation of recruited 
macrophages in addition to AMs by binding to CD200 receptor. Moreover, lung 
epithelial cells constitutively express latent TGF-β which was shown to maintain 
pulmonary immunological homeostasis under steady state. It can get activated by 
influenza NA activity. In vivo blockage of TGF-β during influenza infection was shown 
to increase disease morbidity, implying its potential immunomodulatory activity [55, 64, 
65]. 
 
 
Immune Evasion by Influenza Viruses 
 
 To be successful against the elaborate host immunity, influenza viruses use a 
variety of strategies to evade host immune responses. Several viral proteins have been 
shown to antagonize antiviral innate immune responses and alter the type I IFN response. 
For example, functional influenza NS1 protein can interfere with RIG-I receptor 
signaling at several stages. Furthermore, NS1 may also impair DC maturation, thereby 
indirectly limiting adaptive immunity development. Other viral proteins, including PB2, 
PB1-F2, PB1, and PA also have antagonistic activities against the type I IFN response 
[56, 66, 67]. 
 
 More strikingly, influenza viruses have a unique ability to change their genome. 
Thus, they can evade host adaptive immunity post continuous threats to humans, even to 
a vaccinated populations. Influenza viruses can undergo two types of antigenic changes: 
antigenic shift and antigenic drift. Antigenic shift leads to major changes in the viral 
genome through a reassortment process between genes of different influenza virus strains 
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in a cell simultaneously infected with two of more strains. These reassortment events 
mostly take place in avian or swine reservoirs, resulting in the emergence of a new strain 
that can be transmitted to and circulate among hosts of the same species or transmitted to 
humans, causing recurrent epidemics or global pandemics. In contrast, antigenic drift 
results from mutations in viral genes due to the lack of proofreading activity of influenza 
viral RNA polymerase. This leads to minor changes in the antigenic epitopes of the virus, 
mostly in the surface antigens HA and NA. These random mutations are preserved under 
selective pressure of the host influenza-specific adaptive immunity, generating escape 
mutant strains [43, 56]. 
 
 
Streptococcus pneumoniae 
 
 
History 
 
 Streptococcus pneumoniae, also commonly known as pneumococcus, is among 
the first discovered bacterial pathogens causing human diseases. In 1881, pneumococcus 
was independently isolated by George M. Sternberg in the United States and Louis 
Pasteur in France. They described lancet-shaped pairs of spherical bacteria in human 
saliva. They showed that a new septicemic disease developed rapidly after injecting 
rabbits with human saliva, and recovered the same bacteria from infected rabbit blood 
[68]. 
 
 After several nominations, pneumococcus was named Diplococcus pneumoniae in 
1920 due to its observed morphology as pairs of cocci, and its commonly reported ability 
to cause pneumonia in humans [69]. In 1974, it was renamed Streptococcus pneumoniae, 
as it grows in chains in liquid media [68]. 
 
 Since the discovery of pneumococci in the 19th century, they have been heavily 
investigated and played a central role in several breakthrough discoveries. For example, 
studies on pneumococci expanded our understanding of the concept of host humoral 
immunity and the vaccine production, and facilitated the discovery of DNA as genetic 
material which gave rise to Molecular Genetics [68, 70, 71]. Moreover, it accelerated the 
development and use of penicillin and related antibiotics after they showed efficacy in 
treating pneumococcal infections [72, 73]. 
 
 
Identification 
 
 Pneumococci are Gram-positive bacteria belonging to Streptococcus genus which 
are catalase-negative and can ferment glucose to lactic acid. However, pneumococci 
produce alpha-hemolysis when grown on blood agar plates under 5% CO2 conditions. 
Identification through special biochemical tests is based on pneumococcal ability to 
hydrolyze inulin, and its sensitivity to optochin and bile salt [74]. Further classification is 
based on serotyping. The pneumococcus is surrounded by a polysaccharide capsule that 
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is highly antigenic, inducing specific serum antibodies. Antigenic classification of the 
pneumococcal capsule is performed by a capsular swelling test or quellung reaction, 
which allows identification of more than 90 capsular serotypes [75-77]. 
 
 
Virulence Factors 
 
 Pneumococci reside on the mucosal surface of the upper respiratory tract of 
asymptomatic carriers who are the primary reservoir of S. pneumoniae, from which it can 
be transmitted to other individuals by inhalation of respiratory droplets. Alternatively, it 
can spread locally to cause upper or lower respiratory tract infections. It can also invade 
the blood, causing septicemia and meningitis. 
 
 This clinically challenging pathogen has a diverse armament of virulence factors 
helping it switch from the colonization state to a pathogenic nature that causes respiratory 
tract infections or septicemia (Figure 1-5). One of the key virulence factors is the 
polysaccharide capsule, which resists phagocytosis in the absence of capsule-specific 
antibodies. It acts as a shield, preventing complement C3b deposition on the bacterial cell 
wall, thereby protecting the bacteria against opsonin-mediated phagocytosis. It also 
decreases the trapping of pneumococci in neutrophil extracellular traps [76]. Differences 
in the capsular structure led to the identification of more than 90 capsular serotypes with 
varying degrees of virulence [76]. 
 
 The pneumococcal cell wall has characteristic teichoic acid residues attached to 
the peptidoglycan in addition to lipoteichoic acid attached to the bacterial cell membrane. 
Both moieties have phosphorylcholine, which can bind to choline-binding receptors on 
the surface of human cells. In addition, there are several types of pneumococcal surface 
proteins that play important roles in bacterial adherence, colonization, in vivo growth, 
and virulence. Among these surface proteins are choline-binding proteins, including 
pneumococcal surface proteins A and C (PspA and PspC); metal-binding proteins, 
including pneumococcal surface antigen A (PsaA), pneumococcal iron acquisition A 
(PiaA), and pneumococcal iron uptake A (PiuA); and pneumococcal adhesion and 
virulence A (PavA) [76]. 
 
 Pneumococci are also characterized by the expression of autolysins or cell wall 
hydrolases that induce natural pneumococcal cell wall lysis, during the stationary phase 
of growth and facilitate penicillin-induced lysis. The major autolysin, LytA, has been 
shown to be important for pneumococcal virulence, partly by facilitating the secretion of 
another key virulence factor – pneumolysin. In addition, LytA may be released to lyse 
neighboring non-competent pneumococcal cells in a fratricidal manner [78]. By doing so, 
it facilitates genetic exchange between naturally competent pneumococcal cells that 
easily take up and incorporate DNA by homologous recombination. Furthermore, 
autolysin facilitates the release of pneumococcal cell wall fragments and teichoic acids 
that trigger inflammatory reactions and may interfere with phagocyte-mediated 
elimination of live pneumococci [76, 79]. 
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Figure ‎1-5. Streptococcus pneumoniae structure and virulence factors 
 
Reprinted with permission from Nature Publishing Group. Kadioglu A, Weiser JN, Paton 
JC, Andrew PW. The role of Streptococcus pneumoniae virulence factors in host 
respiratory colonization and disease. Nat Rev Microbiol 2008; 6:288-301 [76]. 
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 Pneumolysin is another key virulence factor with diverse functions. When 
secreted in high enough concentrations, it acts as a cholesterol-dependent, pore-forming 
cytotoxin through oligomerization in the host cell membrane. At sub-lytic concentrations, 
it can modulate target cell functions, such as inhibiting ciliary beating of respiratory 
epithelial cells, and augmenting the synthesis of inflammatory cytokines. It may also 
increase pneumococcal virulence by aggravating inflammatory responses during 
pneumococcal infections [76]. Recently, it was shown that pneumolysin triggers IL-1beta 
and IL-18 secretion through NLRP3 inflammasome activation, which probably mediates 
host resistance against pneumococcal infections [80]. 
 
 Moreover, pneumococci can secrete 3 neuraminidase proteins (NanA, NanB, and 
NanC) that are important for pneumococcal in vivo growth. All strains express NanA, 
most strains express NanB, and some strains express NanC [76, 81]. They cleave terminal 
sialic acid residues from host cell surface glycoproteins or soluble host proteins, such as 
lactoferrin. Thereby, they help reveal receptors for bacterial adherence on the host cell 
surface. They can also secrete a zinc metalloprotease called IgA1 protease that targets 
host mucosal IgA1 [76]. 
 
 
Pneumococcal Diseases 
 
 S. pneumoniae is a serious human bacterial pathogen found to be the most 
common causative agent of pneumonia leading to hospitalization. Pneumococci can 
spread locally from the nasopharynx to cause otitis media or sinusitis, or to the lungs, 
probably by microaspiration, causing pneumonia. Beyond the lungs, pneumococci can 
also invade epithelial barriers to the blood circulation, causing bacteremia, or severe 
invasive infections, such as meningitis, with high mortality rates [82, 83]. 
 
 During the transition of pneumococci from nasopharyngeal colonization to 
invasive infections, they undergo phase variation and modulate the expression of several 
virulence factors to become adapted to various microenvironments within the host. 
Among these switches is capsule formation. Maximal capsule expression is critical for 
systemic infections to help escape from various host humoral immunity and phagocytic 
effectors. Therefore, pneumococci isolated from blood are highly encapsulated. In 
contrast, during nasopharyngeal colonization, pneumococci have minimal capsule 
expression to facilitate exposure of pneumococcal adhesins for better attachment to 
respiratory epithelial cells [76]. 
 
 
Innate Immunity 
 
 Host immune responses during pneumococcal infections are multifaceted as 
pneumococci are encountered by several lines of host defense, including innate non-
specific host defense lines, such as mucociliary clearance, complement activation, 
neutrophils and macrophages. In addition, specific adaptive immunity is triggered, 
generating protective humoral and cellular immunity against pneumococcal infections. 
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Several key protective immune effectors were highlighted by observing hosts with 
genetic deficiencies in certain immunity components and showing high susceptibility to 
recurrent pneumococcal infections. Among them are the patients with deficiency in some 
components of the complement system, such as C3, the central component of 
complement activation pathways. Likewise, in old humans or aged mice, increased 
susceptibility to pneumococcal pneumonia is associated with decreased inflammatory 
immune responses, which may stem from the dysfunction of various TLRs in the lungs 
[84, 85]. 
 
 The complement system is a humoral component of innate immunity involving 
more than 30 inactive serum and membrane-bound proteins. They are activated in a 
cascade manner through 3 pathways and release effector molecules with diverse 
functions. Complement activation pathways include the classical pathway, which is 
activated by microbial antigen-antibody complexes or by acute phase proteins bound to 
microbial surface, and the alternative pathway, which is constitutively turned on but to a 
minor extent due to host cell-bound inhibitors. In contrast, activation of the alternative 
pathway is amplified on foreign microbial surfaces due to absence of these inhibitors. 
The third type is the lectin pathway, which is activated upon binding host mannose-
binding lectin to carbohydrates on microbial surfaces. The activation outcomes by any 
pathway comprise 3 major functions: deposition of certain cleaved components on 
microbial surface functioning as opsonins, which enhance phagocytosis; chemotactic 
functions for neutrophils and other inflammatory immune cells; and direct killing of the 
microbe by membrane attack complexes which form pores in the microbial cell surface 
[86]. 
 
 During pneumococcal infections, the classical pathway is the dominant pathway 
for complement activation and innate immunity against pneumococci [87]. It can be 
activated after binding host natural IgM antibodies or acute phase proteins, such as C 
reactive protein, to the pneumococcal surface [84, 88]. Strikingly, secreted pneumolysin 
was found to activate the classical pathway in an antibody-independent manner. 
However, this phenomenon was shown to contribute to pneumococcal virulence by 
activating and consuming the complement away from the pneumococcal surface, thereby 
preventing deposition of activated complement components on the pneumococcal surface 
[89]. 
 
 Respiratory epithelial cells are the first cells to detect pneumococcal colonization 
and infection. They and other local immune cells express a wide range of PRRs. Diverse 
PRRs are triggered during pneumococcal infections and signal activation and chemotaxis 
of host immune cells by inducing the synthesis of different pro-inflammatory cytokines 
and chemokines. Among them, TLR2, expressed on the host cell surface as heterodimers 
with either TLR1 or TLR6, is activated by several pneumococcal-derived lipoproteins, 
such as lipoteichoic acid. Experimental genetic deletion of TLR2 in mice increased 
pneumococcal virulence by impairing efficient innate immune responses [84]. In 
addition, some cytosolic PRRs, such as NOD1 and NOD2, are activated by the cell wall 
of internalized pneumococci [90]. TLR9 is an intracellular endosomal PPR that can 
recognize pneumococcal DNA which is released from spontaneously lysed pneumococci, 
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and enhance bacterial phagocytosis [91] Additionally, pneumolysin augments the 
induction of various inflammatory cytokines and can activate NLRP3, which is important 
for rapid pulmonary clearance of pneumococci in mice [80]. 
 
 Surfactant proteins are highly synthesized in the lungs to prevent the collapse of 
alveoli. Among them, SP-D and SP-A have innate immune functions during pulmonary 
pneumococcal infections by binding to pneumococci and enhancing their phagocytosis 
[92]. 
 
 Cellular innate immune effectors are crucial for early control of the replicating 
pneumococci through phagocytosis and intracellular killing. Among them, resident AMs 
are the critical first line of cellular innate immunity protecting lungs against invading 
bacterial pathogens, including pneumococci [93]. Resident AMs are characterized by 
high phagocytic capacity and play a key role in immunological homeostasis and 
maintenance of the anti-inflammatory milieu in the lungs under steady-state conditions 
[94, 95]. Artificial depletion of AMs in mice enhanced pneumococcal replication in the 
lungs [93, 96]. 
 
 Although pneumococci can resist complement-mediated opsonophagocytosis via 
its polysaccharide capsule, the dynamic surface of resident AMs is characterized by a 
diverse repertoire of surface non-opsonic receptors facilitating efficient phagocytosis of 
encapsulated pneumococci. This repertoire includes class A scavenger receptors, such as 
SR-AI/II and macrophage receptor with collagenous structure receptor (MARCO), as 
well as C-type lectin mannose receptor, which can bind to the pneumococcal capsule, 
thereby playing an important role in early pneumococcal clearance from murine lungs 
[97, 98]. Recently, CD36, a scavenger receptor expressed on the surface of AMs and 
respiratory epithelial cells, was shown to downregulate the early inflammatory response 
while enhancing bacterial phagocytosis in an animal model of pneumococcal pneumonia 
[99]. In addition, downregulation of MARCO receptor or impaired AM functions by TLR 
desensitization after influenza infection may permit respiratory pneumococcal outgrowth 
in animal models of secondary pneumococcal pneumonia [100, 101]. 
 
 Inside AMs, phagocytosed pneumococci are destroyed by the conventional 
intracellular killing mechanisms which involve lysosomal fusion and phagosome 
maturation, accompanied by degradative action of various lysosomal enzymes and 
bacterial cell damage by the NADPH oxidase-catalyzed oxidative burst. However, when 
the intracellular killing capacity of AMs is exhausted, lysosomal permeabilization and 
activation of cathepsin D take place leading to AM apoptosis with consequent killing of 
internalized bacteria. [102]. 
 
 In sub-clinical infections, efficient pulmonary clearance of pneumococci by 
resident AMs is achieved preventing severe inflammatory sequelae. In contrast, when the 
pneumococcal burden overwhelms the phagocytic capacity of resident AMs, secretion of 
pro-inflammatory cytokines and chemokines is increased, mainly from the respiratory 
epithelial cells, inducing recruitment of neutrophils, the second line of cellular innate 
immunity against pneumococci [103]. Neutrophils or polymorph nuclear leukocytes are 
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short-lived circulating immune cells and are the first cells to accumulate at sites of 
pneumococcal infections or colonization. They become the dominant inflammatory 
immune cells in the pneumonic lungs [104]. In addition, γδ T cells may play an important 
role in the host defense against pulmonary pneumococcal infections by promoting 
neutrophil influx in the lungs [105]. 
 
 To kill pneumococci, neutrophils use a diverse armament involving phagocytosis 
and intracellular bacterial killing by a combination of respiratory burst and non-oxidative 
mechanisms. Activation of NADPH oxidase and myeloperoxidase, the primary arm of 
the oxidative mechanism, leads to generation of various oxidizing species with potent 
bactericidal activities. In addition, neutrophils are loaded with intracellular granules that 
release several antimicrobial molecules, such as α-defensins, cathepsin G, lysozyme, 
lactoferrin, and neutrophil elastase, upon fusion with the phagosome [106]. 
 
 Neutrophils are also characterized by a unique mechanism of extracellular 
bacterial killing. This mechanism involves the release of neutrophil DNA strands loaded 
with antimicrobial molecules that form neutrophil extracellular traps (NETs) with potent 
bactericidal activities. Although pneumococci are captured within NETs, they can escape 
NET-mediated killing by secretion of bacterial endonuclease. In addition, the 
pneumococcal capsule can decrease bacterial trapping in NETs. Likewise, increasing 
positive charges over pneumococcal cell surface lipoteichoic acid enhances repulsion 
from the positively charged NETs [107]. 
 
 Besides their bacterial killing functions, neutrophils augment inflammatory 
reactions causing bystander lung injury. The net outcome of the neutrophil influx during 
pneumococcal pneumonia can be beneficial or deleterious, based on the virulence and 
serotype of the pneumococci [108]. 
 
 
Adaptive Immunity 
 
 Adaptive immune effectors are crucial for developing protective immunity during 
pneumococcal infections and conjugated polysaccharide capsule vaccination. B cells and 
subsets of T cells mediate protective adaptive defense against pneumococci. 
 
 Discovery of antibody-mediated immunity against pneumococci was based on 
very early studies in the 19th century on the protective functions of the serum isolated 
from rabbits that were infected or immunized against pneumococcal infections [68] 
Systemic antibodies specific against the pneumococcal polysaccharide capsule are the 
most critical mediator for humoral protective immunity against invasive pneumococcal 
infections. Differences in capsule structure led to production of antibodies with different 
specificities which were the basis for serotyping and identification of more than 90 
serotypes of pneumococci so far. Moreover, several pneumococcal surface proteins, lying 
beneath or interspersed within the polysaccharide capsule, such as PspA and PsaA, are 
immunogenic, inducing the production of pneumococcal-specific antibodies. These 
antigens are conserved among most pneumococcal serotypes; thus their specific 
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antibodies can provide broad protection. However, vaccines composed of individual 
pneumococcal surface antigens are less potent than capsular polysaccharide vaccines, but 
the potency can be synergized if they are combined [109]. 
 
 There are two mechanisms for activating naïve B cells to secrete pneumococcal-
specific antibodies: thymus-dependent and thymus-independent. Polysaccharide capsular 
antigens stimulate terminally differentiated B cell proliferation by crosslinking specific B 
cell receptors followed by secretion of specific antibodies and limited isotype switching 
with the help of activating cytokines. It is considered a thymus-independent manner due 
to the inability of capsular polysaccharides, except zwitterionic polysaccharides, to be 
processed and presented on MHC class II for specific CD4
+
 T cell activation. In humans, 
the isotypes of capsular-specific antibodies are restricted to IgM and IgG2, and to a lesser 
extent IgG1, while they are IgM and IgG3 isotypes in mice [110]. This mechanism 
induces a rapid increase in antibody titers, but it is transient due to the inability to 
generate memory B cells. Therefore, repeated exposure to the capsule does not boost 
specific antibody titers. Although they are elicited in a T cell-independent manner, some 
studies showed a significant influence of CD4
+
 T cells on IgG responses to 
pneumococcal capsular polysaccharides [111]. 
 
 In contrast, pneumococcal surface proteins and other protein antigens can be 
processed and presented for specific CD4
+
 Th cell activation and consequently elicit 
thymus-dependent activation of specific B cells. Thus, B cells undergo clonal expansion 
and differentiation into specific antibody-secreting plasma cells and memory B cells. 
Specific antibody titers increase slowly but last longer and can be boosted by repeated 
antigen exposures due to the presence of specific memory B cells. Likewise, the protein-
conjugated pneumococcal capsular polysaccharide vaccines stimulate Th-dependent B 
cell responses, as the co-expression of proteins with the capsular polysaccharides 
stimulates CD4
+
 Th cells which activate capsular polysaccharide-specific B cell 
responses associated with specific memory development, leading to a superior potency 
over the pure polysaccharide vaccines [109, 110]. 
 
 The protective functions of pneumococcal-specific antibodies are mainly 
implemented through binding to the pneumococcal surface, which enhances 
opsonophagocytosis and clearance of pneumococci through Fc receptors on phagocytes 
or by classical activation of the complement system. The effectiveness of mucosal 
pneumococcal-specific IgA is limited due to bacterial expression of a secreted zinc 
metalloprotease, IgA1 protease that specifically targets human immunoglobulin A1 
(IgA1), which constitutes more than 90% of the IgA in the human airway [76]. 
 
 Additionally, antibody-independent CD4
+
 T cell-mediated immunity has been 
shown to mediate protection against pneumococcal infections [112]. The importance of 
CD4
+
 T cells in the protective immunity is clearly evident in HIV patients, as HIV 
infection results in a 50-fold increased risk of pneumococcal infections that is inversely 
related to CD4
+
 T cell count [113]. In animal studies using intranasal immunization with 
killed pneumococcal whole cell vaccine, pneumococcal-specific CD4
+
 Th17 cells display 
a significant role in the protection against pneumococcal colonization, which is mediated 
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by IL-17A. Their protective role involves inducing recruitment of phagocytes, including 
macrophages and neutrophils, which accelerate pneumococcal clearance [109, 114, 115]. 
 
 The role of CD8
+
 T cells during pneumococcal infections and vaccination is 
controversial. Animal studies using pneumococcus serotype 3 showed an essential role 
for CD8
+
 T cells in antibody-mediated pulmonary protection, but not systemic immunity, 
against pneumococcal infections [116, 117]. In contrast, another study suggested 
suppressive activity of CD8
+
 T cells against capsular polysaccharide-specific antibody 
responses in vaccinated mice [118]. Skewed Th17 cell responses were observed during 
pulmonary pneumococcal infections in mice with genetic deletion of CD8
+
 T cells, which 
may have deleterious inflammatory outcomes [117]. Therefore, the role of CD8
+
 T cell 
responses may be partly justified through their regulatory influence on Th17 cell-induced 
inflammatory activities. 
 
 
Respiratory Bacterial Super-infections 
 
 
Significance 
 
 Influenza and pneumonia caused the largest number of infectious disease-related 
deaths in the United States throughout the 20th century [119]. Respiratory infections still 
cause major public health problems with enormous clinical and socioeconomic burdens. 
The rates of respiratory infections are higher than any other infectious disease worldwide 
[120]. Generally, influenza infections are mild, and most influenza-associated morbidity 
and mortality are not caused by the viral-induced damage itself. Instead, bacterial super-
infections have been among the major reasons for the increased mortality during 
influenza epidemics and pandemics [35]. 
 
 René Laennec, who invented the stethoscope, was the first physician to describe 
the “double” pneumonia as a common fatal complication during an 1803 influenza 
epidemic in France. Throughout the recorded influenza epidemics and pandemics in the 
modern history, secondary bacterial pneumonia (SBP) was a major complication in 
severe and fatally-infected cases [121]. For example, the 1918 H1N1 influenza pandemic 
was devastating, as it killed more than 30 million people worldwide, which is more than 
three times the number of people killed during World War I [122]. Recently, it was 
shown that more than 90% of autopsy lung tissues of the dead people were positive for 
SBP, which was predominantly caused by S. pneumoniae [123]. Furthermore, the lethal 
effects of SBP were also evident during later influenza pandemics in the antibiotic era, as 
more than 50% of the fatal cases during the 1957 H2N2 and the 1968 H3N2 influenza 
pandemics had SBP but with a significant remarkable contribution of Staphylococcus 
aureus [123-125]. In addition, during the 2009 H1N1 influenza pandemic, about 25-50% 
of fatal or severe cases had SBP [35, 36, 126]. In addition, more than 50% of children 
infected with either pandemic 2009 H1N1 influenza or seasonal influenza had bacterial 
co-infection, mainly by Staphylococcus aureus, and S. pneumoniae [127]. 
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 Certain bacterial pathogens have been commonly isolated from patients with 
secondary bacterial infections, such as S. pneumoniae, Staphylococcus aureus, and 
Haemophilus influenzae [123, 128, 129]. Recent analysis of pooled human cases with 
bacterial co-infections from 1950 to 2006 showed that pneumococcus was the most 
common cause of bacterial co-infection with influenza. It accounted for about 40% and 
16% of bacterial co-infections during pandemic and seasonal periods, respectively [128]. 
 
 Given the significant frequency and effect of bacterial super-infections after 
influenza, it is of paramount importance to study this respiratory viral-bacterial 
synergism. Exploring key factors mediating this synergism will facilitate investigating 
effective preventive and therapeutic approaches during seasonal and epidemic influenza 
periods. In addition, it will allow better strategic preparedness for any future influenza 
pandemics. 
 
 
Mechanisms of Respiratory Viral-bacterial Synergism 
 
 Respiratory viral-bacterial synergism is a complex multifactorial phenomenon. It 
involves several viral, bacterial, and host factors contributing to increased susceptibility 
and the pathogenesis of bacterial super-infections following several types of respiratory 
viral infections including influenza. However, the classical dogma explaining this 
synergism has relied on the viral-induced damage in the respiratory epithelium exposing 
more niches for bacterial adherence [35, 130]. This concept would be a major factor in 
viral-bacterial synergism if the synergism was only observed with highly virulent viruses. 
Yet, low pathogenic viruses have also been found to enhance susceptibility to bacterial 
super-infections, as seen with seasonal influenza viruses [131, 132]. 
 
 Four main mechanisms have been proposed to explain this synergism. These 
mechanisms essentially describe factors underlying how primary viral infections establish 
niches for secondary bacterial invaders and support their spread, virulence, and 
outgrowth, while impairing host antibacterial defense lines (Figure 1-6). 
 
 The first category involves factors establishing foothold for secondary bacterial 
pathogens which is the first step in successful bacterial infection. The breakdown of 
respiratory epithelial barrier integrity, due to the death of influenza-infected cells lining 
the airways, exposes extracellular matrix proteins providing more sites for bacterial 
attachment. In addition, influenza NA activity cleaves sialic acid residues on the host 
mucosal surface exposing more receptors for bacterial adherence. Increased viral NA 
activity was shown to support SBP development [133]. This may also be explained by 
facilitating viral spread deep in the lungs. Strikingly, released sialic acid residues, a good 
carbon and energy source, are involved in several activities that support pneumococcal 
biofilm formation in vitro and invasiveness in the lungs [35, 134]. Furthermore, platelet-
activating factor receptor expression is upregulated during influenza infection which may 
enhance pneumococcal invasiveness into the blood. However, it was shown to be 
inessential for SBP progression [35, 135]. 
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Figure ‎1-6. Respiratory viral-bacterial interactions 
 
Reprinted with permission from PLOS. Bosch AA, Biesbroek G, Trzcinski K, Sanders 
EA, Bogaert D. Viral and bacterial interactions in the upper respiratory tract. PLoS 
pathogens 2013; 9:e1003057 [136]. 
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 The second category involves factors facilitating bacterial spread deep in the 
lungs. Several respiratory viral infections, such as influenza and respiratory syncytial 
virus infection, inhibit mucociliary beating. Thereby, they impair early mechanical 
clearance of invading bacteria from the trachea, which promotes deep bacterial spread 
within the lungs [137, 138]. Additionally, viruses with higher tropism to replicate deep 
within the lungs, such as the 2009 pandemic H1N1 influenza virus, may establish niches 
for secondary bacterial pathogens causing lower respiratory tract infections and SBP [35]. 
 
 The third category proposes bidirectional synergistic interactions between 
influenza viruses and the secondary bacterial pathogens, rather than the previous 
mechanisms that involve unidirectional effects through the influenza viral pathogenicity 
in the lungs. Indeed, specific pairings of viral and bacterial pathogens show successful 
synergism in the lungs. In addition, different bacterial strains have remarkable differences 
in their disease potential after primary influenza viral infection [139]. Bacterial virulence 
factors may augment the pathogenesis of primary influenza virus infections. However, 
only few of these factors are known [139]. For instance, proteases from Staphylococcus 
aureus showed a synergistic effect on the infectivity of influenza viruses by activating 
HA by cleavage, which increased co-infection pathogenicity [140]. Other examples of 
bidirectional interactions include synergistic inflammatory responses during secondary 
bacterial infections. Pathogenesis of primary influenza infections is believed to be mainly 
due to inflammatory cytokine responses and host immunopathology. During bacterial co-
infections, the host immunopathology is augmented at the site of infection. However, this 
interaction is usually observed in a synergistic rather than an additive fashion, which 
might be due to the remarkable increase in expression of certain PRRs in the lungs and 
some circulating immune cells during influenza infections, such as TLR2, TLR3, and 
TLR9 [141, 142]. Additionally, during the acute phase of the primary influenza infection, 
the accumulated inflammatory immune cells would add to the total numbers of the 
detecting system in the lungs. Thus, in addition to ongoing inflammatory responses 
during influenza infection, secondary bacterial invaders elicit synergistic inflammatory 
reactions after activating more PRRs and more immune cells. However, genetic deletions 
of some TLRs, such as TLR2, did not prevent SBP development or lethal bacterial co-
infections [143, 144]. 
 
 The last category of the proposed mechanisms underlines the dysfunction of host 
antibacterial immunity during primary influenza infections which leads to uncontrolled 
bacterial outgrowth. Pathogenic bacteria invading terminal airways are encountered by 
the host first line of innate defense composed of specialized highly phagocytic cells 
within the alveolar airspaces – the resident AMs. Several studies of animal models 
reported phagocytic dysfunction in AMs during influenza infections [145-148]. A more 
recent study attributed this dysfunction to IFNγ-mediated downregulation of the 
expression of a certain scavenger receptor, MARCO receptor, on the surface of AMs. 
Thereby, their phagocytic capacity was decreased, and early pneumococcal clearance was 
impaired during the resolution phase of sublethal influenza infection when adaptive 
immune cells infiltrate the lungs with increased IFNγ production [101]. In addition, in 
vitro incubation of murine macrophages with IFNγ may decrease macrophage expression 
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levels of another scavenger receptor – the mannose receptor, and phagocytic functions 
against certain bacterial pathogens [149, 150]. 
 
 Viral PB1-F2 protein has also been implicated in viral-bacterial synergism and its 
associated lung immunopathology. This viral protein is the product of an alternate open 
reading frame of the PB1 viral gene segment in some influenza virus strains, with 
variable expression in infected host cells leading to strain-specific pathogenicity [9]. It 
has multifunctional properties, mainly contributed to by its pro-apoptotic and pro-
inflammatory motifs [151]. Its expression leads to an enhanced inflammatory response 
and lung immunopathology, contributing to the increased mortality in murine models of 
SBP [152-154]. Furthermore, it has been suggested that it may induce the death of AMs, 
thereby contributing to the impairment of antibacterial innate immunity during influenza 
infections [155]. 
 
 Impaired functions of murine NK cells during influenza infections have also been 
implicated to contribute to the enhanced susceptibility to secondary Staphylococcal 
infections, probably by decreasing the opsonophagocytic functions of AMs gated as 
CD11b
hi
 Gr1
low
 CD11c
low
 cells [156]. However, the role of NK cells in the pulmonary 
antibacterial immunity is still controversial and needs to be fully examined with a variety 
of bacterial pathogens [157, 158]. 
 
 Neutrophils are considered the second line of innate immune cells, as they are 
recruited to the lungs when resident AM phagocytic functions are impaired or 
overwhelmed. Influenza A viruses may accelerate human neutrophil apoptosis in vitro 
[159]. In addition, neutrophil dysfunction has been proposed to contribute to increased 
bacterial super-infections after influenza infection [160]. However, the researchers found 
that pneumococcal titers increased only with co-infection 6 days after influenza infection, 
although neutrophil dysfunction was seen 3 and 6 days after influenza infection. In 
addition, they depleted neutrophils using anti-GR1 RB6-8C5 monoclonal antibody, 
which is a non-selective antibody that could also deplete monocytic cells expressing 
Ly6C marker, thereby confounding the results [160]. Furthermore, they used a relatively 
high dose of pneumococcus in their co-infection model, thus overwhelming AM 
phagocytic capacity. Thus, they ended up examining neutrophil functions. Taken 
together, the exact impact of influenza infections on neutrophil functions and whether 
this effect really contributes to increased vulnerability to bacterial super-infections still 
need to be carefully investigated. 
 
 Late after recovery from influenza infection, another mechanism of immune 
dysfunction has been suggested by the findings of TLR desensitization in the lungs. This 
mechanism relies on the enhancement of bacterial super-infections by impairing efficient 
detection of bacterial pathogens by AMs. Thus, it leads to ineffective innate immune 
responses against secondary bacterial infections [100]. However, this desensitization lasts 
for several months, which is not clinically relevant to the timing window for successful 
secondary bacterial infections observed in the first 2 weeks after influenza infection. 
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 In addition, the early upregulation of the type I IFN response during influenza 
infection or the increased IL-10 production after the recovery of influenza infection has 
been suggested to inhibit neutrophil influx which may contribute to the impaired 
antibacterial innate defense. However, disrupting their signaling pathways provided only 
partial or minimal resistance against secondary bacterial infections, which was linked to 
increased neutrophil recruitment and/or functions [161, 162]. Furthermore, increased type 
I IFN expression during influenza infection was suggested to suppress IL-17 secretion 
from γδ T cells that may play important role in recruiting neutrophils during pulmonary 
bacterial infections. Abrogating their signaling by genetic deletion of IFN alpha receptor 
improved bacterial clearance and protected mice against SBP following influenza 
infections [147, 163].  
 
 Efficient repair of influenza-induced epithelial damage is critical to restoring lung 
homeostasis and functions. However, during bacterial co-infections, the repair process of 
damaged epithelial cells is significantly impaired which may contribute to the lethality of 
bacterial co-infections [144, 164]. 
 
 In summary, several mechanisms have been proposed with varying levels of 
evidence supporting their significant contribution to the enhanced susceptibility to 
secondary bacterial infections following influenza and/or their increased lethality. The 
current prophylactic and therapeutic measures against this serious medical problem are 
targeting the infectious agents with either vaccinations or antimicrobial agents, 
respectively. Indeed, much of these approaches succeeded in decreasing the significance 
of respiratory secondary bacterial infections compared to the 1918 influenza pandemic 
time or before. Nonetheless, in the influenza pandemic in 2009-2010, secondary bacterial 
infections complicated more than one third of severe and fatal cases, even with 
comprehensive diagnosis and treatment strategies. Many factors may have been involved 
in this failure, among them is the reported increased emergence of resistant strains of 
influenza viruses and secondary bacterial pathogens [165-167]. Furthermore, antiviral 
therapy can only display effective prevention of SBP if administered early during primary 
influenza infection by shortening the duration of viral shedding [35, 168]. Therefore, 
investigating the effect of primary influenza infections on the host pulmonary 
antibacterial immunity has become of paramount importance, as novel prophylactic or 
therapeutic approaches based on immunomodulation would be more effective in breaking 
this synergism by augmenting the host immunity against many secondary bacterial 
pathogens simultaneously. 
 
 
Lung-resident Macrophages 
 
 Lungs are part of the respiratory system with unique structure and very critical 
functions for the human body through blood re-oxygenation at the terminal regions of the 
lungs – the alveoli. With a very large surface area of about 70 m2 in adult humans and 
continuous exposure to the external environment with a thin epithelial layer away from 
the pulmonary capillaries, the alveoli look like a short step away from disaster [169]. 
Therefore, a complex immune regulatory network functions to maintain the lungs in a 
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quiescent non-inflamed state. Critical players in this network are the lung-resident 
macrophages. 
 
 There are two major subsets of lung-resident macrophages: AMs residing in the 
alveolar lumen within the surfactant thin layer over the alveolar epithelial surface, and 
interstitial macrophages (IMs) residing in the lung parenchymal tissue. Under steady state 
conditions, AMs are the major hematopeotic cells in the alveolar airspaces. They were 
first isolated via pulmonary alveolar lavage technique in 1961 [170]. Since that time, 
several groups have studied the functions and ontology of pulmonary macrophages which 
suggested developmental and functional differences between lung-resident AMs and IMs 
[94, 171, 172]. IMs were suggested as precursors for resident AMs with intermediate 
maturation stage, while AM ontogeny from circulating blood monocytes or by local 
macrophage proliferation is still under debate [172-174]. Under inflammatory stimuli, 
such as influenza infections, different exudate monocytes and macrophages are recruited 
to the lungs which have different functional phenotypes and probably transcriptional 
profiles from the lung-resident macrophages [53, 54]. 
 
 Resident AMs play a pivotal role in the immune surveillance in the lungs. 
Because of their high phagocytic capacity and strong microbicidal activities, they are 
considered the first line of innate defense against inhaled particles and bacterial 
pathogens [94, 171]. In addition, they display immunosuppressive activities and poor 
antigen presenting capability in vitro and in vivo which may be critical to prevent 
harmless environmental particulates from triggering detrimental inflammatory reactions 
in the lungs [171, 175-179]. In contrast, IMs have lower phagocytic capacity but better 
antigen presenting activities, as they express more surface MHC class II molecules and 
can effectively induce T cell proliferation [94].  
 
 Therefore, investigating the impact of influenza infections on the lung-resident 
macrophages in vivo is an attractive area, as it may elucidate part of the complex puzzle 
of respiratory viral-bacterial synergism by explaining how influenza infection alters the 
cellular innate immune defense in lungs and establishes a niche for the development of 
SBP. This will also open avenues for novel immunomodulating prophylactic and 
therapeutic interventions to prevent SBP during both pandemic and seasonal influenza 
periods. 
 
 
Scope and Objectives of Dissertation 
 
 
Specific Aim 1: To Determine the Impact of Influenza Infection on the Lung-
resident Macrophages In Vivo 
 
 Sub-aim 1.1. To characterize and differentiate between subsets of lung-resident 
macrophages and recruited macrophages using in vivo labeling approach. 
 
 27 
 Sub-aim 1.2. To track dynamic changes of labeled lung-resident macrophages 
during PR8 influenza infection. 
 
 Sub-aim 1.3. To determine if loss of resident alveolar macrophages during 
influenza infection is due to increased cell death process. 
 
 
Specific Aim 2: To Determine if Depletion of Resident Alveolar Macrophages 
during Influenza Infection Contributes to Enhanced Susceptibility to Secondary 
Pneumococcal Pneumonia 
 
 Sub-aim 2.1. To determine if early pneumococcal clearance within alveolar 
airspaces is impaired during the depletion phase of resident alveolar macrophages after 
influenza infection. 
 
 Sub-aim 2.2. To determine if the impaired early pneumococcal clearance 
facilitates pneumococcal pneumonia development during the depletion phase of resident 
alveolar macrophages after influenza infection. 
 
 
Specific Aim 3: To Test if Expanding the Lung-resident Macrophage Pool Can 
Protect Influenza-infected Mice against Secondary Pneumococcal Pneumonia 
 
 Sub-aim 3.1. To test if local GM-CSF treatment can replenish the alveolar 
macrophage pool during influenza infection. 
 
 Sub-aim 3.2. To determine if the expanded pool of resident pulmonary 
macrophages, by local GM-CSF treatment, can restore early pneumococcal clearance and 
prevent secondary pneumococcal pneumonia in influenza-infected mice. 
 
 
Specific Aim 4: To Test if Adjunctive Immunomodulator Therapy Can Improve 
Outcomes during Bactericidal Antibiotic Treatment of Secondary Pneumococcal 
Pneumonia  
 
 Sub-aim 4.1. To determine influence of the lung pneumococcal burden on the 
lung immunopathology and mortality outcomes during ampicillin treatment of secondary 
pneumococcal pneumonia. 
 
 Sub-aim 4.2. To test efficacy of corticosteroid therapy before or combined with 
ampicillin treatment of mice with mild or severe secondary pneumococcal pneumonia. 
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CHAPTER 2.    IMPACT OF INFLUENZA INFECTION ON THE LUNG-
RESIDENT MACROPHAGES IN VIVO
1
 
 
 
Introduction 
 
 Influenza and pneumonia are leading causes of morbidity and mortality in both 
children and adults in the United States [180]. In developing countries, acute lower 
respiratory infections are the leading cause of death in children younger than 5 years of 
age [181]. Most influenza-related mortality is not due to the viral infection alone. Instead, 
secondary bacterial pneumonia complicates many severe cases in influenza-infected hosts 
[35]. This results in a tremendous economic burden due to increased hospitalizations, 
medical costs, and indirect costs during both pandemic and inter-pandemic influenza 
periods [123]. Complicating the picture, treatment of secondary bacterial pneumonia may 
not be successful even in the antibiotics era. Globally increased rates of antimicrobial 
resistance among many common respiratory bacterial pathogens and the mechanisms of 
the drugs themselves can both complicate treatment and cure [165, 166, 182, 183]. The 
continuous threat of a new influenza pandemic makes it crucial to understand how 
influenza infection alters the host’s local innate immunity to the benefit of establishing 
secondary bacterial infections. 
 
 Lungs are protected against bacterial infections by various components of innate 
and adaptive immunity [44, 184]. Influenza-infected patients are vulnerable to bacterial 
super-infections, suggesting defects in some or all of these resistance and clearance 
mechanisms. Certain bacterial pathogens have been commonly isolated from patients 
with secondary bacterial infections, such as S. pneumoniae [123, 128, 129]. Immunity to 
S. pneumoniae is not completely understood at present in intact or compromised hosts. 
Among host innate immune players, resident AMs are considered to be the most 
prominent first line of defense against respiratory pneumococcal infections [93], through 
their high phagocytic capacity [94-96]. 
 
 Resident AMs therefore represent an intriguing target for study. However, the 
strategies for differentiation of resident macrophage subsets in the airways and lung 
tissues are insufficient to distinguish AMs from lung-resident IMs or inflammatory 
monocytic cells invading the lung in response to infections. In some studies, AMs have 
been putatively identified based on their surface immunophenotype as CD11c
hi
 F4/80
hi
 
cells. Indeed, CD11c and F4/80 surface markers are highly expressed on the AM surface, 
but some inflammatory macrophages/ dendritic cells can express these markers as well 
[185-187]. Thus, gating on these two markers only will not differentiate the various types 
of cells during influenza infection, potentially leading to erroneous conclusions about the 
absolute numbers of resident macrophages. 
                                                   
 
1
 Adapted with permission from The American Association of Immunologists, Inc. 
Ghoneim HE, Thomas PG, McCullers JA. Depletion of Alveolar Macrophages during 
Influenza Infection Facilitates Bacterial Superinfections. J Immunol 2013; 191:1250-9. 
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 Using a novel in vivo labeling approach combined with extensive flow cytometric 
analyses and confocal microscopic examination, we efficiently labeled and characterized 
different subsets of lung-resident macrophages in lungs of naïve mice. We then 
investigated the impact of sublethal influenza A virus infections on the two major subsets 
of lung-resident macrophages – alveolar and interstitial macrophages – using a murine 
model of sublethal influenza infections using different influenza virus strains. 
 
 
Materials and Methods 
 
 
Influenza Viruses 
 
 We used the St. Jude strain of mouse-adapted influenza virus A/Puerto Rico/8/34 
(H1N1), referred to as “PR8”, as well as the human clinical isolate of the pandemic 
influenza virus A/California/04/09 (H1N1) referred to as “pdm H1N1”. All viruses were 
passaged once through Madin-Darby canine kidney (MDCK) cells, stocks were grown by 
a single passage through eggs, and allantoic fluid was stored at −80°C. The viral titers of 
the stocks were characterized via median tissue culture infective dose (TCID50) assay in 
MDCK cells.  
 
 
Mice 
 
 Six- to 8-week old female BALB/c mice (Jackson Laboratory, Bar Harbor, ME) 
were maintained in a Biosafety Level 2 facility in the Animal Resource Center at St. 
Jude. Animals were given general anesthesia that consisted of 2.5% inhaled isoflurane 
(Baxter Healthcare Corporation, Deerfield, IL) prior to all interventions, and all studies 
were approved by the Animal Care and Use Committee at St. Jude. 
 
 
Infectious Model 
 
 Infectious agents were diluted in sterile phosphate buffered saline (PBS) and 
administered intranasally in a volume of 100 μl (50 μl per nostril) to anesthetized mice 
held in an upright position. In all experiments of influenza infection, PR8 influenza virus 
was given at a dose of 25 doses infectious for 50% of tissue culture wells (TCID50) per 
100 µl per mouse, which caused about 10% weight loss on day 7 after infection and no 
mortality when given alone. The virus infectious dose in the pdm H1N1 experiment was 
600 TCID50 per mouse, which caused morbidity and weight loss comparable to PR8 
infection (data not shown). 
 
 
 
 30 
In Vivo Labeling of Lung-resident Macrophages 
 
 One hundred µl of 10 mM PKH26-PCL dye (Sigma-Aldrich, St. Louis, MO) was 
intranasally administered into anesthetized mice 5 days before influenza infection, as 
previously described [101]. 
 
 
Flow Cytometric Analysis of Immune Cells in Bronchoalveolar Lavage Fluid, Post-
lavage Lungs, and Mediastinal Lymph Nodes  
 
 Following euthanasia by CO2 inhalation, the trachea was exposed and cannulated 
with a 24-gauge plastic catheter (Becton Dickinson Infusion Therapy Systems, Inc., 
Sandy, UT). Lungs were lavaged 4 times with 1 ml of cold sterile Hank’s buffered salt 
solution (HBSS) supplemented with 0.1 mM ethylenediaminetetraacetic acid 
(EDTA).The whole lungs after lavage or mediastinal lymph nodes were harvested and 
physically homogenized by syringe plunger against a 40-µm cell strainer and washed in 
FACS buffer consisting of HBSS, 0.1 mM EDTA, and 1% heat-inactivated fetal bovine 
serum. Cell suspension of bronchoalveolar lavage fluid (BALF), post-lavage lung 
homogenate, or mediastinal lymph nodes homogenate were centrifuged at 4°C, 350 × g 
for 7 min, and the BALF supernatant was stored at –80°C. Flow cytometry (LSRII, and 
LSRII Fortessa, Becton Dickinson, San Jose, CA) was performed on the cell pellets after 
incubation with 75 μl of 1:200 dilution of Fc block (anti-mouse CD16/CD32, BD 
Bioscience Inc., San Jose, CA) on ice for 10 min, followed by surface marker staining 
with anti-mouse antibodies conjugated with different fluorescent probes: CD11c (eFluor 
450), F4/80 (FITC), Ly6G (PerCp-Cy5.5), Ly6C (APC), and CD11b (APC-eFluor 780; 
eBioscience Inc., San Diego, CA). The data were analyzed using FlowJo 8.8.6 (Tree Star, 
Ashland, OR) where viable cells were gated from an FSC/SSC plot. First, neutrophils 
(CD11b
hi
 Ly6G
hi
) were gated out, then macrophages (CD11c
hi
 F4/80
hi
) were sub-gated 
based on CD11b surface expression into AMs (CD11b
-
), IMs (CD11b
low-int
), and 
recruited exudate macrophages (CD11b
hi
). Viable and non-viable cells were counted 
before surface marker staining, and the percentage viability was counted via the trypan 
blue exclusion method using a Cell Countess System (Invitrogen, Grand Island, NY). The 
absolute numbers of different cell types were calculated based on the proportion of viable 
events analyzed by flow cytometry as related to the total number of viable cells per 
sample. Live/dead aqua dye was added during flow cytometric surface staining to 
determine the total numbers of dead AMs and IMs. This dye binds to free amines after 
penetrating the impaired cell membrane of dead cells. First, AMs and IMs were gated as 
mentioned above but without prior gating for viable events based on forward scatter and 
side scatter (FSC/SSC) dot plot. Live/dead aqua-positively stained AMs and IMs were 
gated as dead cells, and their numbers were calculated based on the proportion of dead 
events from the total events, analyzed by flow cytometry. Average mean fluorescence 
intensity of PKH26-PCL was measured for different subsets of macrophages in the PE 
channel. 
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Confocal Laser Scanning Microscopy of PKH26-labeled Lungs 
 
Five days after in vivo PKH26-PCL labeling of lung macrophages, euthanasia by 
CO2 inhalation was performed, and the trachea was exposed and cannulated with a 24-
gauge plastic catheter (Becton Dickinson Infusion Therapy Systems, Inc., Sandy, UT). 
Lungs were harvested after instillation of 1.2 ml of 4% freshly prepared formaldehyde 
with PBS. Harvested lungs were fixed in 4% formaldehyde with PBS at room 
temperature for 1 hour. Every lung was then washed with PBS and cut into 4 pieces 
before mounting into PBS in 4 wells of Nunc Lab-Tek chambered cover glass (Thermo 
Scientific, Rochester, NY) before microscopic examination. Fluorescence was visualized 
with a Nikon Eclipse TE2000-E inverted microscope equipped with C2 confocal system 
and a 40X/1.3NA numeric aperature oil objective (Nikon Instruments, Melville, NY). 
Image collection and analysis were performed with Nikon NIS-Elements software 
(Version 4.13). 
 
 
Cytospin Slides Preparation 
 
After harvesting BALF as described above, and before staining cells for flow 
cytometry analysis, BALF cells were resuspended in PBS, cytospun (Thermo Scientific, 
Ashville, NC) onto glass slides, and stained with Diff-Quick (Quik-Dip stain; Mercedes 
Medical, Sarasota, FL). Neutrophils, monocytes/macrophages, and lymphocytes were 
identified by morphology and images were taken from different representative fields of 
stained macrophages under high power fields. 
 
 
Statistical Analysis 
 
 Comparison of cell counts, and mean fluorescence intensity of PKH26-PCL in 
BALF, and post-lavage lung homogenate between groups were compared using analysis 
of variance (ANOVA). Mann-Whitney U test was used for pair-wise comparisons of 
mean fluorescence intensity of PKH26-PCL between AMs and IMs in fixed lungs under 
confocal microscopy, or comparisons of Ly6C surface expression between AMs, and 
IMs, or recruited macrophages. A p-value of < 0.05 was considered significant for these 
comparisons. Prism 4 for Windows (GraphPad Software, Inc., V 4.03) was used for all 
statistical analyses. 
 
 
Results 
 
 
In Vivo Labeling of Lung-resident Macrophages Can Distinguish Alveolar 
Macrophages from Interstitial Macrophages 
 
 Before examining any alterations in the lung-resident innate immune cells in 
influenza-infected hosts, we determined critical techniques for the differential analysis of 
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the heterogeneous population of macrophages in both alveolar airspaces and post-lavage 
lung tissue. First, we refined a flow cytometry technique for gating resident macrophages 
so that clear differentiation between different cells types could be accomplished. We used 
the common markers CD11c
hi
 and F4/80
hi
 and added gating by another marker, CD11b 
(β2-integrin). CD11b has been shown to be weakly expressed on AM cell surface [172, 
188, 189] while highly expressed on granulocytes, exudate macrophages, monocytes, and 
some dendritic cells [190-193]. Therefore, AMs are better gated as CD11c
hi
 F4/80
hi
 
CD11b
dim
 in BALF as shown recently [189, 194]. This allowed differentiation in our flow 
cytometric analysis of the two major subsets of lung-resident macrophages in mock-
infected mice. Thus, AMs could be gated as CD11c
hi 
F4/80
hi
 CD11b
-
 and IMs as CD11c
hi 
F4/80
hi
 CD11b
low-int
 in both BALF and post-lavage lung homogenate (Figure 2-1A). 
 
 To confirm our gating strategy for both subsets of lung-resident macrophages and 
to differentiate them from recruited macrophages, we did in vivo labeling of lung-
resident macrophages before influenza infection using intranasally administered 
PKH26-Phagocytic Cell Labeling (PKH26-PCL) dye. Both subsets of lung-resident 
macrophages were intensely labeled by the dye, showing high means of the fluorescence 
intensity of PKH26-PCL dye (MFI-PKH26). Nonetheless, significant differences in MFI-
PKH26 were observed between AMs and IMs in both BALF and post-lavage lung 
homogenates, with IMs showing significantly lower MFI-PKH26 than AMs (Figure 
2-1B). Additionally, selective labeling of lung-resident macrophages was confirmed by 
confocal microscopy of fixed naïve PKH26-labeled lungs showing the same pattern of 
difference in PKH26-MFI (Figure 2-2). These differences reflect the spatial and 
functional differences between the two major subsets of lung-resident macrophages, with 
IMs having less accessibility to the intranasally administered dye and lower phagocytic 
capacity than AMs [94, 172, 195]. Thus, the in vivo labeling method confirmed the 
validity of our flow cytometric gating strategy for the lung-resident macrophage subsets. 
 
 
Influenza Virus Infection Depletes Alveolar Macrophages 
 
 To determine if influenza infection causes any alteration in the numbers of lung-
resident macrophages, we determined the percentages of lung-resident macrophages in 
flow cytometric dot plots and calculated their absolute numbers. We infected BALB/c 
female mice intranasally with the mouse-adapted H1N1 influenza virus strain A/Puerto 
Rico8/34 (PR8) using a sublethal dose (25 TCID50 per 100 µl). Seven days after 
influenza virus infection, more than 90% of the AM pool was depleted (Figure 2-3A). To 
exclude the possibility that the observed depletion of AMs is unique to the use of a 
mouse-adapted influenza virus strain (PR8), we examined changes in the AM pool size 
using a sublethal dose of a human clinical influenza isolate from the 2009 influenza 
pandemic, the A/California/04/09 H1N1 strain (pdm H1N1). We found that AMs were 
significantly depleted within 7 days after pdm H1N1 infection to levels comparable to 
PR8 infection (Figure 2-3B). Furthermore, we also tested the impact of sublethal 
influenza B virus infection in vivo, and we found significant depletion of resident AMs 
on days 3 and 5 after infection (data not shown). 
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Figure ‎2-1. Differentiation between lung-resident macrophages subsets 
 
(A) Flow cytometry dot plots show the gating strategy of resident alveolar macrophages 
(AMs, R4 gate) and interstitial macrophages (IMs, R5 gate) in BALF (top plots) and 
post-lavage lungs (bottom plots) of mock-infected mice. (B) In vivo labeling of lung-
resident macrophages using PKH26-PCL dye before influenza infection can distinguish 
AMs (solid red bars) from IMs (solid black bars) based on the mean fluorescence 
intensity (MFI) of PKH26-PCL dye in both BALF and post-lavage lungs (n = 4). 
***P < 0.001 by Tukey's multiple comparison test (ANOVA). The bar graphs show the 
average ± SD. 
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Figure ‎2-2. Fluorescence microscopic examination of PKH26-labeled naive lungs 
confirms selective in vivo labeling of lung-resident macrophages 
 
(A) Photomicrographs show that both AMs (arrow) and IMs (asterisk) are selectively 
labeled by PKH26-PCL dye and emit red PKH26 fluorescence. Green autofuorescence 
can be detected from AMs, IMs, and elastin and collagen fibers. (B) AMs have 
significantly higher PKH26-MFI and autofluorescence compared with that of IMs 
measured from 3 different fields. Images were obtained by a Nikon Eclipse TE2000-E 
microscope (n=3). 
**P < 0.01 by Mann-Whitney U test. The bar graphs show the average ± SD. 
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Figure ‎2-3. Lung-resident alveolar macrophages are depleted during influenza 
virus infections 
 
Absolute numbers of AMs in bronchoalveolar lavage fluid (solid bars) and post-lavage 
lungs (open bars) of PR8-infected (A), or 2009 pandemic H1N1-infected mice (B), 
analyzed 7 days after influenza infection, are significantly lower than in mock-infected 
(naive) mice (n ≥ 5, in each group of mock-infected or influenza-infected mice). 
***P < 0.001 by Mann-Whitney U test, compared with mock-infected (naïve) mice. The 
bar graphs show the average ± SEM. 
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Tracking of Lung-resident Macrophage Dynamic Changes during Influenza 
Infection 
 
 To track depletion kinetics of AMs and changes of the IM pool size during 
influenza infection, we again did in vivo labeling of lung-resident macrophages followed 
by sublethal PR8 influenza infection and studied different time points in the first 2 weeks 
after influenza virus infection. We found that AMs were significantly depleted in the 
alveolar airspaces shortly after PR8 infection starting on the first day p.i. (Figure 2-4A). 
Considering that some AMs may not be completely harvested in BALF and still adhere to 
the respiratory tract lining, we also analyzed post-lavage lungs and found that higher 
numbers of AMs remained in the post-lavage lung homogenate. These remaining AMs 
were significantly depleted starting 3 days p.i. compared with those in mock-infected 
mice (Figure 2-4B). Consequently, 3 days after PR8 influenza infection was identified as 
the earliest time point of significant whole lung AM depletion. The AM pool was 
partially replenished 9 days p.i. (in BALF only), while complete replenishment appeared 
11 days p.i. (Figure 2-4A and B). Conversely, the IM pool was not significantly depleted 
during the course of influenza infection; however, it was expanded at later time points 
(Figure 2-4A and B). 
 
 By tracking dynamic changes in MFI-PKH26 of AMs and IMs after PR8 
influenza infection, we observed that MFI-PKH26 of AMs significantly decreased during 
the full replenishment period starting 11 days p.i (Figure 2-5A and B). In contrast, MFI-
PKH26 of IMs decreased shortly after influenza infection without significant changes in 
their absolute numbers observed in the post-lavage lungs in the first week of infection 
(Figure 2-4B and Figure 2-5B). However, in the second week, the IM pool significantly 
expanded with a significant increase in their absolute numbers harvested from BALF 
(Figure 2-4A). This may suggest partial depletion of IMs pool which can be quickly 
restored through their rapid proliferative capacity. 
 
 
Validity and Stability of the In Vivo Labeling Approach to Distinguish Different 
Subsets of Pulmonary Macrophages during the Tracking Period 
 
 To confirm the validity of the tracking process of lung-resident macrophages 
during the course of influenza infection, dynamic changes in their MFI-PKH26 were 
measured. At any time point after influenza infection, AMs showed the highest MFI-
PKH26 compared to IMs or recruited exudates macrophages (Figure 2-6A and B), 
despite the observed decrease in MFI-PKH26 of AMs during their full replenishment 
period starting 11 days p.i. (Figure 2-5A and B). Thus, it confirms our flow cytometric 
gating strategy that differentiates between resident AMs and IMs, and newly recruited 
exudate macrophages. 
 
 We did further characterization of the different macrophage subsets in the lungs 
during influenza infection based on their surface expression levels of Ly6C antigen that 
can be used to differentiate between resident and recruited inflammatory macrophage 
subsets, in addition to their maturation stages [191, 192]. We found that resident AMs did  
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Figure ‎2-4. Tracking of lung-resident macrophage dynamic changes during 
influenza infection 
 
Absolute numbers of resident AMs and IMs in BALF (A) and post-lavage lungs (B) of 
PR8-infected mice harvested 1, 3, 5, 7, 9, 11, and 14 days p.i (n ≥ 4). 
*P < 0.05,**P < 0.01,***P < 0.001 by Dunnett's multiple comparison test (ANOVA), 
compared with mock-infected (naïve) mice. Data are expressed as the average ± SD. 
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Figure ‎2-5. Dynamic changes of the mean fluorescence intensity of PKH26-PCL 
of the lung-resident macrophages during influenza infection 
 
Tracking the changes in MFI (mean fluorescence intensity) of PKH26-PCL dye of 
resident AMs and IMs in BALF (A) and post-lavage lungs (B) at different time points 
during influenza infection (n ≥ 4). 
*P < 0.05,**P < 0.01,***P < 0.001 by Dunnett's multiple comparison test (ANOVA), 
compared with influenza-infected mice 1 day p.i. Data are expressed as the average ± SD. 
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Figure ‎2-6. Differential mean fluorescence intensity of PKH26-PCL dye of 
different pulmonary macrophage subsets during influenza infection 
 
Comparisons of MFI-PKH26 (mean fluorescence intensity of PKH26-PCL) of different 
pulmonary macrophage subsets, including resident AMs, IMs, and recruited macrophages 
in BALF (A) and post-lavage lungs (B) during the course of influenza infection (n ≥ 4). 
*P < 0.05,**P < 0.01 by Dunnett's multiple comparison test (ANOVA), compared with 
AMs at each time point. The bar graphs show the average ± SD. 
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not express surface Ly6C, while resident IMs express intermediate levels, reflecting their 
intermediate stage of maturation and supporting the previous studies suggesting IMs as 
precursors for AMs [172, 196]. In contrast, the recruited exudates macrophages with 
CD11b
high
 phenotype showed significantly high expression levels of Ly6C (Figure 2-7). 
 
 We also determined the stability of PKH26-PCL dye in vivo in the mock-infected 
lungs, to exclude the possibility that these observed changes in PKH26-MFI of lung-
resident macrophages after influenza infection were not due to instability of the dye, but 
rather due to changes in resident macrophage pool size via maturation of unlabeled 
macrophages. PKH26-PCL dye demonstrated efficient labeling and stability inside the 
lung-resident macrophages for at least 14 days after mock-infection (i.e. 19 days after 
labeling), thereby covering the tracking period during which we did the kinetics analyses 
(Figure 2-8). 
 
 
Ontogeny of the Replenished Pool of Alveolar Macrophages after Influenza 
Infection 
 
 To determine origin of the replenished AM pool during the resolution phase of 
influenza infection, we sub-gated AMs based on the fluorescence intensity of 
PKH26-PCL dye into PKH26
high
, PKH26
int
, and PKH26
-
 subsets. We then measured the 
frequencies of these 3 sub-populations as percentages of total numbers of resident AMs. 
Surprisingly, the PKH26
-
 subset did not virtually contribute to the replenishment of 
resident AM pool, implying a neglected contribution of the recruited, non-labeled, 
macrophages in resident AM homeostasis. Instead, more than 75% of AM pool after full 
replenishment was composed of PKH26
high
 subset (on days 11 and 14 p.i), suggesting 
their probable origin from PKH26
high
 IMs after differentiation and maturation into the 
resident AM phenotype (Figure 2-9). 
 
 The remaining portion of the replenished AMs consists of PKH26
int
 subset and 
represents about 25% of total replenished AMs (Figure 2-9). Its intermediate level of 
PKH26-PCL fluorescence intensity suggests that it developed through proliferation of the 
remaining PKH26-labeled AMs or PKH26-labeled IMs followed by maturation into the 
AM phenotype. 
 
 
Influenza Infection Induces Cell Death of Alveolar Macrophages 
 
 To determine whether AM depletion is due to a cell death process, we measured 
the total numbers of dead AM cells during PR8 infection using a cell viability dye 
(live/dead aqua). The total numbers of dead AMs were significantly higher in both BALF 
and post-lavage lungs of influenza-infected mice than in mock-infected mice (Figure 
2-10A). In contrast, there was no significant difference between the total numbers of dead 
IMs in influenza-infected and mock-infected mice (Figure 2-10B). To determine the type 
of AM cell death process, we examined alveolar macrophages for any morphologic 
changes associated with influenza infection. Diff-Quick -stained cytospin slides of BALF 
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Figure ‎2-7. Differential surface expression of Ly6C marker on different 
pulmonary macrophage subsets 
 
Ly6C-MFI are compared at different time points after influenza infection. 
**P < 0.01, ***P < 0.001 by Mann-Whitney U test, where AMs are compared with IMs, 
and IMs are compared with recruited MФ at each time point (n ≥ 4). The bar graphs show 
the average ± SD. 
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Figure ‎2-8. Fluorescence intensity of PKH26-PCL dye is stable in lung-resident 
macrophages for 2 weeks after mock infection 
 
% PKH26-MFI values are calculated as percentages of the average PKH26-MFI of AMs 
on day 3 after PBS administration (n ≥ 4). 
*P < 0.05 by Dunnett's multiple comparison test (ANOVA), compared with % PKH26-
MFI of AMs on day 3 after PBS. The bar graphs show the average ± SD. 
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Figure ‎2-9. Ontogeny of the replenished alveolar macrophage pool during 
influenza infection 
 
Alveolar macrophages were sub-gated based on degree of PKH26-PCL labeling into 
PKH26
high
, PKH26
int
, and PKH26
-
 subsets. Then frequencies of each sub-population were 
measured as percentages of total numbers of AMs at different time points after PR8 
influenza infection (n = 6-8).  
The bar graphs show the average ± SD. 
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Figure ‎2-10. Influenza infection induces significant alveolar macrophage cell death 
 
Total numbers of dead AMs (A) and IMs (B) are calculated during influenza infection. 
(C) Cytospin of Diff quick-stained BALF cells from mock-infected and PR8-infected 
mice 3 days p.i at magnification × 500. 
*P < 0.05,**P < 0.01 by Dunnett's multiple comparison test (ANOVA), compared with 
mock-infected naive mice. The bar graphs show the average ± SD. 
 
 
 45 
cells harvested from influenza-infected mice 3 days p.i. showed many macrophages with 
cellular damage manifestations. They were characterized by distorted nuclei and more 
vacuoles in cytoplasm than in mock-infected mice (Figure 2-10C). This suggests that 
cell death was due to a secondary necrotic process. 
 
 To determine if AMs were lost due to recruitment to the lung-draining lymph 
nodes, we examined the mediastinal lymph node 7 days after PR8 influenza infection and 
did not observe significant recruitment of PKH26-labeled AMs to it (data not shown). 
 
 
Discussion 
 
 In this chapter, we determined the impact of sublethal influenza infections on the 
two major subsets of murine lung-resident macrophages in vivo. Dramatic depletion of 
resident AMs, but not IMs, takes place for a certain period during influenza infection, in 
association with a remarkable increase in the dead AM cell numbers early after infection. 
This depletion was not only observed during infection by a mouse-adapted H1N1 
influenza A virus strain (PR8), but it was also shown during sublethal infections using 
human clinical isolates of the 2009 pandemic H1N1 influenza A virus and influenza B 
virus. 
 
 Tracking the PKH26-labeled AMs during PR8 influenza infection revealed a 
temporary depletion process from day 3 to day 9 after infection under the infection 
settings and with the mouse strain which we used. About 70% of AMs were depleted 
after 3 days, reaching a nadir (> 90% depletion) 7 days after PR8 influenza infection. 
This matches the previously established boundaries for maximum synergism in the 
secondary bacterial infection model [197], which parallel the typical order and timing of 
infections in humans [198]. Interestingly, in another influenza infection model using a 
different strain, percentage of resident AMs – gated as CD11chigh Mac-1- - decreased on 
day 3 p.i [199], which is consistent with our findings. However, the authors did not show 
the absolute numbers of these cells. 
 
 Efficient replenishment of the AM pool then took place during the resolution 
phase of influenza infection. We investigated the ontogeny of the replenished AMs, and 
found that their pool was mainly recovered through local proliferation and differentiation 
of IMs into AM phenotype. Strikingly, our novel findings were also recently suggested 
by another research group that used a genetic approach to track genetically labeled lung-
resident macrophages during PR8 influenza infection. They showed significant lung-
resident macrophage cytoablation on day 6 after influenza infection and suggested that 
these macrophages could repopulate later, mainly by local proliferation [173]. 
 
 We highlighted the critical requirement for using approaches that could efficiently 
distinguish between different lung-resident macrophage subsets – AMs and IMs, and 
differentiate them from the inflammatory macrophages and DCs recruited during lung 
infections. Indeed, the PKH26-PCL in vivo labeling approach combined with the flow 
cytometric analyses and confocal microscopic examination could efficiently label and 
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characterize different subsets of lung-resident macrophages in the lungs of naïve mice, in 
addition to differentiating them from recruited unlabeled immune cells. Therefore, one 
observation stemming from our findings is that examination of lung-resident 
macrophages in the setting of influenza infection should be cautiously performed. During 
influenza infection, diverse chemokines are upregulated in lungs, activating an influx of 
heterogeneous populations of innate immune cells, such as monocytes, inflammatory 
macrophages, and monocyte-derived dendritic cells. The dynamic changes in the 
phagocyte populations in influenza-infected lungs require critical methods to distinguish 
resident macrophages from recruited ones. Based on the surface phenotype of lung-
resident macrophages in naïve mice, we used an extensive gating strategy to analyze and 
differentiate resident and recruited macrophages. Thus, AMs were gated as CD11c
hi 
F4/80
hi
 CD11b
-
, while IMs and recruited macrophages were gated as CD11c
hi 
F4/80
hi
 
CD11b
low-int
 and CD11c
hi 
F4/80
hi
 CD11b
high
 respectively. Further characterization showed 
the ability of the Ly6C marker to differentiate between resident and recruited phagocytes 
and their maturation stage in influenza-infected lungs. Ly6C antigen is expressed by 
circulating blood monocytes and macrophages, which can be recruited to tissues under 
inflammation conditions [191]. However, Ly6C expression is down-regulated during 
differentiation of blood monocytes or macrophages into tissue resident macrophages after 
migration to tissue. Therefore, it can be added as a suitable marker to differentiate 
macrophage subsets and their stages of maturation into tissue resident phenotype [192]. 
Moreover, in vivo labeling of lung-resident macrophages was done to validate our gating 
strategy and to distinguish between resident AMs and recruited macrophages. The 
PKH26-PCL dye used to label macrophages forms fluorescent microparticles, which can 
be taken up by the resident phagocytes in the lungs. The dye remains stable 
intracelullarly for more than 21 days [101], and emits high fluorescence intensity for at 
least 19 days based on our findings. 
 
 Furthermore, monitoring changes of MFI-PKH26 for lung-resident macrophages 
reflected the dynamic changes in their absolute numbers during influenza infection. For 
instance, expansion of the AM pool during the recovery phase was accompanied by 
significant decrease in their MFI-PKH26. Nevertheless, the AM population showed the 
highest MFI-PKH26 at various times during the first 2 weeks after influenza infection. 
Thereby, the significantly high MFI-PKH26 of AMs during their replenishment phase in 
addition to the high percentages of PKH26
high
 sub-populations implied that the AM pool 
was mainly replenished via local proliferation and differentiation of the PKH26-labeled 
IMs into an AM surface phenotype, rather than maturation of PKH26-unlabeled recruited 
blood macrophages. In contrast, the quick drop in MFI-PKH26 of IMs in the first week 
after influenza infection, without apparent changes in their absolute cell numbers, 
suggests that influenza infection may induce partial depletion of the IM pool. However, 
this partial depletion can be quickly re-compensated by the proliferative capacity of IMs, 
maturation of the recruited macrophages, or both [94, 172]. 
 
 Several investigators, who used animal models of influenza infections, couldn’t 
identify depletion of resident AMs during influenza infections because of some 
limitations in their analysis. Mostly they used gating strategies not sufficient to 
distinguish between resident AMs, IMs, and recruited exudate macrophages. For 
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example, gating for a single marker like F4/80 antigen or macrophage-specific esterase 
staining of macrophages isolated from BAL fluid during influenza infection is targeting 
mixed populations of resident and recruited macrophages whose total cell numbers 
increase during infection [200]. In addition, although the same in vivo labeling method 
was used before, AM depletion couldn’t be identified during influenza [101]. Based on 
their analysis, they gated AMs as CD11c
+
 PKH26
+
 which may be mixed with IMs. They 
analyzed AM numbers on day 9 after influenza infection in BAL fluid only. Based on our 
model, we showed certain period for AM depletion from day 3 to day 9 after influenza 
infection. Analyzing depletion events by monitoring AMs at a single time point (day 9 
p.i) during influenza infection is inconclusive. Furthermore, analyzing cells in BAL fluid 
may cause us to miss AMs that remain adherent in the lungs after lavage leading to the 
underestimation of the resident AM pool size during the comparison between influenza-
infected and mock-infected mice. Likewise, in another study the authors did not show 
AM depletion because of missing CD11b marker in their AM gating, as well as 
harvesting only BAL fluid for kinetics analysis [185]. Taken together, missing an 
important marker that distinguishes between different lung-resident macrophage subsets 
and recruited monocytic cells or using BAL fluid only for analyzing resident AMs may 
lead to erroneous conclusions regarding their kinetics during infections.  
 
 In summary, sublethal influenza infection induces transient depletion of the 
resident AMs, which temporally parallels the period of the increased clinical 
susceptibility to SBP following influenza infections in humans. These findings led us to 
propose a novel mechanism of influenza-mediated immunosuppression in the lungs. 
However, whether this proposed mechanism contributes to the increased vulnerability to 
SBP still needs to be experimentally tested. 
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CHAPTER 3.    DEPLETION OF RESIDENT ALVEOLAR MACROPHAGES 
DURING INFLUENZA INFECTION CONTRIBUTES TO ENHANCED 
SUSCEPTIBILITY TO BACTERIAL PNEUMONIA
2
 
 
 
Introduction 
 
 Bacterial super-infections are among the common complications during influenza 
infections. Specifically, SBP has been found complicating significant percentages of 
severe cases and deaths during periods of influenza outbreaks and seasonal influenza. 
Furthermore, SBP remarkably contributed to the increased mortality during several 
influenza pandemics even after antibiotics discovery and their wide routine use. For 
instance, in the last 2009 influenza pandemic, 25%-50% of severe or fatal cases had SBP 
[35, 36, 126]. 
 
Mechanisms of the increased predisposition to SBP following influenza infections 
have been investigated for a long time [35, 147, 201]. Several studies have been 
performed to explain the synergistic interactions between influenza viruses and secondary 
bacterial pathogens. Previous studies of viral-bacterial synergism in our laboratory have 
focused on influenza virus virulence factors and their damaging effects on respiratory 
tract epithelial cells, together with synergistic inflammatory lung injury during co-
infection [35, 129]. However, our findings in Chapter 2 provided insights of a novel 
mechanism underlying the increased permissiveness to SBP through influenza-induced 
loss of the most critical innate immune cells in the lungs – the resident AMs. 
 
 Lung-resident AMs are considered the most important cells of the first line of 
innate defense against respiratory pneumococcal infections [93] due to their high 
phagocytic capacity [94-96]. We reasoned that early escape from the first line of defense 
in the lungs could have profound effects on immunity to a variety of pathogens, including 
secondary bacterial invaders. Enhanced bacterial growth and replication through this 
mechanism could allow enhanced expression of virulence factors and the resulting 
inflammatory response. Therefore, we sought to determine if the resident AM depletion 
during influenza infection contributes to the enhanced susceptibility to SBP. 
Additionally, we tested an immunomodulation intervention to prevent this defect in the 
antibacterial immunity by expanding the lung-resident macrophage pool during influenza 
infection so that it might protect influenza-infected mice against SBP. 
 
 We used standard murine influenza virus infection and co-infection models [202], 
in which BALB/c female mice are infected intranasally by a sublethal dose of influenza 
A virus – this primary infection may then be followed by a sublethal dose of S. 
pneumoniae at different time points after influenza infection. We demonstrated that 
                                                   
 
2
 Adapted with permission from The American Association of Immunologists, Inc. 
Ghoneim HE, Thomas PG, McCullers JA. Depletion of Alveolar Macrophages during 
Influenza Infection Facilitates Bacterial Superinfections. J Immunol 2013; 191:1250-9. 
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resident AM depletion impairs early bacterial clearance, supporting development of SBP 
during the AM depletion phase. These data have implications for understanding virus-
induced host immune suppression that may lead to improved prevention and treatment of 
primary or secondary infections in the lungs. 
 
 
Materials and Methods 
 
 
Infectious Agents 
 
 For influenza infections, we used PR8 influenza virus and prepared the infectious 
dose from the same stocks as described previously (page 29). 
 
 For secondary bacterial infections, we used the clinical human isolate of S. 
pneumoniae A66.1, a type 3 encapsulated strain. It was engineered to express luciferase 
(Kevin Francis and Jun Yu, Xenogen Corporation, Alameda, CA). Pneumococci were 
grown in Todd Hewitt broth (Difco Laboratories, Detroit, MI) to an OD620 of 
approximately 0.4 and then frozen at −80ºC mixed 2:1 with 5% sterile glycerol. The titers 
of the frozen stocks were quantitated on tryptic soy agar (Difco Laboratories, Detroit, 
MI) supplemented with 3% v/v sheep erythrocytes (blood agar). In all instances, the 
infectious dose administered was confirmed by serial dilution and plating of the bacterial 
suspension on blood agar plates. 
 
 
Mice 
 
 Six- to 8-week-old female BALB/c mice (Jackson Laboratory, Bar Harbor, ME) 
were maintained in a Biosafety Level 2 facility in the Animal Resource Center at St. 
Jude. Animals were given general anesthesia that consisted of 2.5% inhaled isoflurane 
(Baxter Healthcare Corporation, Deerfield, IL) prior to all interventions, and all studies 
were approved by the Animal Care and Use Committee at St. Jude. 
 
 
Infectious Model 
 
 Infectious agents were diluted in sterile PBS and administered intranasally in a 
volume of 100 μl (50 μl per nostril) to anesthetized mice held in an upright position. In 
all experiments of influenza infection, PR8 influenza virus was given at a dose of 25 
TCID50 per 100 µl per mouse, which did not cause mortality when given alone. In co-
infection experiments, PR8 infection was followed at the specified time point by 
pneumococcal challenge with 200 colony forming units (CFUs) per mouse. Infected mice 
were weighed and assessed daily for illness and mortality for 7 days after pneumococcal 
challenge. 
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Imaging of Live Mice 
 
 Mice were then imaged for 60 seconds using an IVIS CCD camera (Caliper Life 
Sciences, Alameda, CA) daily after pneumococcal challenge to monitor in vivo 
pneumococcal pneumonia development. Total photon emission from selected and defined 
areas within the images of each mouse was quantified using Living Image software 
(Caliper Life Sciences, Alameda, CA) as described previously [152, 203, 204] and 
expressed as the flux of relative light units per minute. Pneumonia was defined as visible 
bioluminescence within the thorax and detection of a flux of > 11,000 relative light units 
per minute. 
 
 
Flow Cytometric Analysis of Immune Cells in BALF and Post-lavage Lungs  
 
 Following euthanasia by CO2 inhalation, the trachea was exposed and cannulated 
with a 24-gauge plastic catheter (Becton Dickinson Infusion Therapy Systems, Inc., 
Sandy, UT). Lungs were lavaged 4 times with 1 ml of cold sterile HBSS supplemented 
with 0.1 mM EDTA. The whole lungs after lavage were harvested and processed, in 
addition to BALF cell suspension, for surface marker staining as described previously 
(page 30). AMs and IMs were gated as described previously (page 30). Viable and non-
viable cells were counted before surface marker staining, and the percentage viability was 
counted via the trypan blue exclusion method using a Cell Countess System (Invitrogen, 
Grand Island, NY). The absolute numbers of different cell types were calculated based on 
the proportion of viable events analyzed by flow cytometry as related to the total number 
of viable cells per sample. 
 
 
Determination of Early Pneumococcal Clearance 
 
 Early pneumococcal clearance was determined by measuring the pneumococcal 
count remaining within alveolar airspaces. Briefly, mice were euthanized by CO2 
inhalation 3 h after pneumococcal inoculation. BALF was harvested using sterile HBSS 
supplemented with 0.1 mM EDTA (lavage by 1 ml twice), and then half the BALF was 
spread on blood agar plates supplemented with 0.4 mg kanamycin/ml blood agar to select 
for kanamycin-resistant luciferase-expressing pneumococci [203] and incubated at 37°C 
overnight. 
 
 
Local GM-CSF Treatment Regimen 
 
 We treated anesthetized mice intranasally with 25 µg of recombinant mouse GM-
CSF (Granulocyte/Monocyte-Colony Stimulating Factor, Invitrogen, Grand Island, NY) 
in 100 µl of sterile PBS on days –1 and +1 before and after PR8 infection. We treated 
control mice with vehicle (PBS) only. 
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Statistical Analysis 
 
 Comparison of survival and pneumonia development between groups of mice was 
done with the log-rank chi-squared test on the Kaplan-Meier survival data. Comparison 
of bacterial titers, and cell counts in BALF, and post-lavage lung homogenate between 
groups were compared using analysis of variance (ANOVA). Comparison of weight loss 
between groups of mice was done using Mann-Whitney U test for pair-wise comparisons. 
A p-value of < 0.05 was considered significant for these comparisons. Prism 4 for 
Windows (GraphPad Software, Inc., V 4.03) was used for all statistical analyses. 
 
 
Results 
 
 
Influenza Infection Enhances Susceptibility to Secondary Pneumococcal Pneumonia 
 
 Influenza-mediated death of AMs is likely to have significant effects on primary 
and secondary immunity. To explore one potential defect, we studied the permissiveness 
of influenza-infected hosts to secondary respiratory bacterial infections. We first infected 
BALB/c female mice intranasally with PR8 influenza virus using a sublethal dose (25 
TCID50). Influenza-infected mice showed mild morbidity manifested as loss of about 
10% of their original body weight within 7 days after influenza infection (Figure 3-1A). 
At that time point, we induced secondary bacterial infection via intranasal administration 
of a small inoculum (200 CFUs) of the serotype 3 clinical isolate of S. pneumoniae, 
A66.1. Influenza-infected mice showed high susceptibility to secondary pneumococcal 
infection with a significant increase in morbidity and continuous body weight loss 
(Figure 3-1A). All co-infected mice died within 3 to 5 days after pneumococcal 
inoculation (Figure 3-1B). In contrast, all single influenza- or single pneumococcus-
infected mice recovered quickly with no mortality (Figure 3-1A and B). To determine 
whether the co-infected mice died due to pneumococcal pneumonia, we monitored 
pneumococcal growth in vivo through bioluminescent imaging of the lungs [203]. Only 
co-infected mice developed serious pneumococcal infections; pneumonia occurred within 
48 h after pneumococcal inoculation (Figure 3-1C). Likewise, sublethal influenza B 
virus infection enhanced the susceptibility to develop lethal secondary pneumococcal 
pneumonia, if influenza-infected mice get secondarily infected with 200 CFUs of 
pneumococci at time points with significant AM depletion (data not shown). 
 
 
AM Depletion during Influenza Infection Impairs Early Pneumococcal Clearance 
 
 To determine whether the observed depletion of the AM pool contributes to 
enhanced susceptibility to secondary pneumococcal infection in influenza-infected hosts, 
AM phagocytic function was assessed in vivo by measuring early pneumococcal 
clearance with or without influenza infection. First, we determined the earliest time point 
at which a small pneumococcal inoculum (200 CFUs) could be efficiently cleared within 
the alveolar airspaces of naive mice. Pneumococcal early clearance was tested at different 
 52 
 
 
 
Figure ‎3-1. Murine influenza-pneumococcal co-infection model 
 
Body weight loss (A) and survival rate (B) of single pneumococcal-infected (PBS and S. 
pneumoniae (St. pn.), n = 6), single influenza-infected (influenza and PBS, n = 8), and 
co-infected (influenza and S. pneumoniae, n = 9) mice with 7 days interval between two 
doses in each group. (C) Thorax bioluminescence of luciferase-expressing A66.1 
pneumococcus from 3 representative co-infected mice showing development of 
pneumococcal pneumonia. Images were taken 48 h after secondary bacterial challenge 
using 200 CFUs of pneumococcus on day 7 after influenza infection. (D) Pneumococcal 
titers harvested 3 h after bacterial inoculation (inoculum of 200 or more CFUs) from 
alveolar airspaces of mock-infected and influenza-infected mice 7 days p.i. are shown as 
percentage of inoculum. 
*** P < 0.001 by Mann-Whitney U test, compared at each time point with single 
influenza-infected mice group (Panel A), by log-rank test on the Kaplan Meier survival 
data (Panel B), or by Dunnett's multiple comparison test (ANOVA), compared with 
mock-infected mice (Panel D). Data represent the average ± SD. 
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time points (1, 2, 3, and 4 h) after bacterial inoculation. Complete pneumococcal 
clearance was observed within 3 h after pneumococcal inoculation in naïve mice (data 
not shown). Then, we tested the ability of influenza-infected lungs to clear this small dose 
of pneumococcus (200 CFUs) at this early time point. This experiment demonstrated that 
early pneumococcal clearance was significantly impaired in the alveolar airspaces of 
influenza-infected mice compared with mock-infected controls. Mock-infected mice 
could efficiently clear more than 95% of up to 50-fold higher doses of pneumococcus, 
while influenza virus-infected mice were unable to clear the basal inoculum (Figure 
3-1D).  
 
 
Influenza-infected Mice Demonstrate Increased Susceptibility to Secondary 
Pneumococcal Pneumonia during the AM Depletion Phase 
 
 To determine whether AM depletion during influenza infection correlates with the 
susceptibility to secondary pneumococcal infection, we examined the early 
pneumococcal clearance at different time points after influenza infection. Early 
pneumococcal clearance was significantly impaired during PR8 infection from 3 until 9 
days p.i. (Figure 3-2A). This period of early pneumococcal clearance impairment closely 
mirrors the phase of the AM pool depletion observed during PR8 infection (Figure 2-4A 
and B). Later, after the full replenishment of the AM pool, the impaired early 
pneumococcal clearance was restored starting from day 11 p.i (Figure 3-2A). 
 
 To determine whether the impaired early pneumococcal clearance during 
influenza infection enhances susceptibility to secondary pneumococcal pneumonia 
development, we monitored mouse lungs via bioluminescence imaging 24 h after 
bacterial inoculation. Among the influenza-infected mice, 100% developed secondary 
pneumococcal pneumonia when they were secondarily infected by pneumococcus 3, 5, or 
7 days after influenza infection. In contrast, all influenza-infected mice that were 
secondarily infected either 1 days or 14 days p.i. cleared the bacterial dose efficiently and 
did not develop secondary pneumococcal pneumonia (Figure 3-2B). Secondary 
pneumococcal pneumonia development was less frequent in influenza-infected mice that 
were secondarily infected by pneumococcus on 9 or 11 days p.i., with only 60% or 40% 
of pneumonic mice, respectively (Figure 3-2B). As expected in this model, all co-
infected mice that developed secondary pneumococcal pneumonia died within few days 
due to bacterial pneumonia (Figure 3-2C). 
 
 
Local GM-CSF Treatment Expands the Lung-resident Macrophage Pool in 
Influenza-infected Mice 
 
 To restore the early bacterial clearance efficiency that was impaired during the 
AM depletion phase, we tested local recombinant GM-CSF treatment as a means to 
accelerate replenishment of the depleted AM pool in influenza-infected mice. 
Recombinant GM-CSF was intranasally administered in 2 doses on days –1 and +1 
before and after PR8 infection (Figure 3-3A). First, we analyzed the effect of this 
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Figure ‎3-2. Successful co-infection synergism during the AM depletion phase in 
influenza-infected mice 
 
(A) Pneumococcal CFUs, as percentages of inocula, harvested 3 h after bacterial 
inoculation (inoculum of 200 CFUs) from the alveolar airspaces of mock-infected and 
influenza-infected mice 1, 3, 5, 7, 9, 11, and 14 days p.i. Secondary pneumococcal 
pneumonia development (B) and mortality (C) are manifested in influenza-infected mice 
that are secondarily pneumococcal-infected during the AM depletion phase (D.1 group; n 
= 5, D.3 group, n = 6; D.5 group, n = 4; D.7 group, n = 10; D.9 group, n = 5; D.11 group, 
n = 5; and D.14 group, n = 5 ). 
*P < 0.05, ** P < 0.01, ***P < 0.001 by Dunnett's multiple comparison test (ANOVA), 
compared with mock-infected mice (Panel A), or compared with Day 1 or Day 14 co-
infection groups by log-rank test on the Kaplan Meier survival data (Panel B and C). 
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Figure ‎3-3. Local GM-CSF treatment expands the lung-resident macrophage pool 
in influenza-infected mice 
 
(A) Diagram showing local GM-CSF treatment regimen, where recombinant GM-CSF 
was intranasally administered into PR8-infected mice on days –1 and +1 before and after 
infection. Then BALF and post-lavage lungs were harvested for analysis of lung-resident 
macrophages. (B) The absolute numbers of AMs and IMs increased in GM-CSF-treated 
influenza-infected mice analyzed 3 days p.i (n ≥ 4). 
*P < 0.05,***P < 0.001 by Dunnett's multiple comparison test (ANOVA), compared 
with mock-treated mock-infected mice. The bar graphs show the average ± SD. 
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GM-CSF treatment regimen on the size of the AM and IM pools. Local GM-CSF 
treatment in influenza-infected mice resulted in a significant expansion of the IM pool 
with partial replenishment of the AM pool (Figure 3-3B). 
 
 
Local GM-CSF Treatment Decreases the Susceptibility to Secondary Pneumococcal 
Pneumonia Following Influenza 
 
 To evaluate the efficacy of local GM-CSF treatment in the co-infection model, 
pneumococcus was administered 3 days after PR8 infection into GM-CSF-treated and 
mock-treated mice groups (Figure 3-4A). Local GM-CSF treatment led to better early 
pneumococcal clearance in influenza-infected mice than in mock-treated mock-infected 
mice. Conversely, early pneumococcal clearance remained impaired in mock-treated, 
influenza-infected mice (Figure 3-4B). Interestingly, some of the GM-CSF-treated 
influenza-infected mice could efficiently clear the bacterial inoculum, while others could 
not. Next, we tested the ability of local GM-CSF treatment to prevent secondary 
pneumococcal pneumonia development after bacterial inoculation 3 days p.i. Local GM-
CSF treatment protected more than 50% of co-infected mice against secondary 
pneumococcal pneumonia. Meanwhile, all mock-treated co-infected mice developed 
pneumococcal pneumonia (Figure 3-4C). 
 
 
Discussion 
 
 Influenza is well known to increase susceptibility to secondary bacterial 
infections, such as SBP. The increased permissiveness of influenza-infected lungs to 
pneumococcal outgrowth suggests a defect in the host innate immune defenses that 
establishes a niche for bacterial infections. In this Chapter, we examined a novel 
mechanism of influenza-mediated immune suppression, which is the depletion of resident 
AMs. The resulting immune defect is likely to have pleiotropic effects on primary and 
secondary immunity. We examined one potential effect; bacterial escape from early 
innate immunity contributing to enhanced vulnerability to SBP. Resident AMs are 
essential for early bacterial clearance and protection against bacterial infections [93, 101]. 
We found that early clearance of small pneumococcal inocula was significantly impaired 
during the AM depletion phase. The impaired early bacterial clearance correlated with 
successful progression to SBP. 
 
 In most studies of primary or secondary pneumococcal pneumonia in animal 
models, AM-mediated protection has not been rigorously studied [101, 147, 205]. This 
appears mainly to be because of the use of high doses of pneumococcus (≥ 1×105 CFUs) 
to overwhelm the phagocytic capacity of resident AMs and induce a robust and 
reproducible pneumonia. Under these settings, neutrophil influx coupled with the 
development of early adaptive response in the form of serotype-specific antibody was 
found in these models to be important for host protection against primary pneumococcal 
pneumonia [84, 104, 161]. However, in the perhaps more physiologically relevant setting 
of a relatively small dose of pneumococcus (200 CFUs) after sublethal mild influenza 
 57 
 
 
 
Figure ‎3-4. Local GM-CSF treatment decreases the susceptibility to secondary 
pneumococcal pneumonia following influenza 
 
(A) Diagram showing local recombinant GM-CSF treatment into PR8-infected mice on 
days –1 and +1 before and after infection, followed by intranasal administration of 200 
CFUs of pneumococcus on day 3. GM-CSF treatment improved early pneumococcal 
clearance within the alveolar airspaces (B) and secondary pneumococcal pneumonia 
development (C) compared with mock-treated co-infected mice (GM-CSF-treated group, 
n = 9, PBS-treated group, n = 4). 
**P < 0.01 by Dunnett's multiple comparison test (ANOVA), compared with mock-
treated mock-infected mice (Panel B), or *P < 0.05 by log-rank test on the Kaplan Meier 
survival data, compared with mock-treated co-infected mice (Panel C). 
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infection, we could demonstrate a strong effect mediated by AMs. This low bacterial 
inoculum successfully caused lethal secondary pneumococcal pneumonia within 48-72 h 
after bacterial inoculation, pneumonia that was mainly dependent on an absence of the 
resident AMs. 
 
 GM-CSF is a cytokine with diverse functions and is known to be critical for 
effective innate immunity in lungs. It regulates AM differentiation and activation [188, 
206], enhances proliferation of resident pulmonary macrophages [173, 192], and expands 
the pool of resident AMs [207]. It also has an important role in pulmonary surfactant 
homeostasis [208]. Recent studies showed that GM-CSF over expression in lungs has 
prophylactic activity against lethal influenza and pneumococcal pneumonias [207, 209, 
210]. We found that local recombinant GM-CSF treatment in influenza-infected mice 
induced significant expansion of the IM pool. In addition, absolute numbers of AMs 
increased under this treatment regimen in influenza-infected mice. This increase was less 
than that of IMs, possibly because they were analyzed at an earlier time point (3 days p.i). 
Our data are consistent with previous studies showing that GM-CSF enhances the 
proliferation capacity of lung-resident macrophages and maturation of AMs. Considering 
the higher proliferative capacity of IMs over AMs, our short treatment regimen could 
significantly expand the pool of IMs more than AMs. As a result of the partial 
replenishment of the AM pool with pulmonary GM-CSF treatment, influenza-infected 
mice had partial restoration of efficient early pneumococcal clearance. Furthermore, they 
manifested improved protection against secondary pneumococcal pneumonia. Although 
pulmonary GM-CSF treatment has some drawbacks such as inflammatory activity [211] 
that can render its use in humans problematic by exacerbating inflammatory lung injury, 
the results of our study are promising. They suggest that strategies seeking to balance the 
protective AM replenishment effects and the adverse effect of exuberant inflammation 
induction via combining an adjunctive anti-inflammatory therapy with GM-CSF 
treatment may be successful. 
 
 Overall, these findings suggest a novel mechanism of influenza-mediated immune 
suppression that resulted in increased permissiveness of influenza-infected hosts to SBP. 
Resident AM depletion during influenza infection establishes a niche for secondary 
pneumococcal infection by altering early cellular innate immunity in the lungs, thereby 
allowing pneumococcal outgrowth causing lethal pneumococcal pneumonia. The precise 
functional characterization of this novel finding can change the way researchers look at 
the alteration of pulmonary cellular innate immunity during sublethal influenza 
infections. There are likely to be important effects on immunity beyond the bacterial 
escape studied here. Furthermore, these findings open avenues for novel 
immunomodulating therapeutic interventions to prevent respiratory bacterial super-
infections by quick replenishment of the critical innate immune effectors during both 
pandemic and seasonal influenza. 
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CHAPTER 4.    ADJUNCTIVE IMMUNOMODULATOR THERAPY IMPROVES 
MORTALITY DURING ANTIBIOTIC TREATMENT OF SECONDARY 
PNEUMOCOCCAL PNEUMONIA 
 
 
Introduction 
 
 Globally, pneumonia is the leading killer of children outside of the neonatal 
period [181]. In addition, there has been little change in mortality due to respiratory tract 
infections for more than five decades [119, 120]. SBP is a common complication of 
influenza, and outcomes are worse in co-infections than in uncomplicated cases [35, 
212]. In the 1918 influenza pandemic, the majority of deaths were complicated by SBP, 
and S. pneumoniae was the predominant pathogen [123]. However, the advent of 
antibiotic therapy in 1940s and the widespread use of effective pneumococcal vaccines in 
the developed world decreased the frequency of pneumococcal diseases over the last 
century. Nonetheless, S. pneumoniae continues to be the leading bacterial cause of 
community-acquired pneumonia (CAP) and SBP [213]. For example, during the 2009 
H1N1 influenza pandemic, 25% to 50% of severe or fatal cases were complicated by 
SBP, mostly with S. pneumoniae and Staphylococcus aureus [35, 126, 214]. 
 
 These severe outcomes including mortality are seen in patients with SBP despite 
appropriate antimicrobial treatment [212, 215]. Although globally increased rates of 
antimicrobial resistance among common respiratory bacterial pathogens are a concern 
[165, 166], the mechanism of killing utilized by standard antibiotics also appears to affect 
treatment outcomes [183, 204]. Ampicillin is considered the first line therapy for 
bacterial pneumonia in hospitalized children, including those co-infected with influenza 
[216]. In a murine model of SBP following influenza, treatment with ampicillin was 
shown to induce robust inflammatory lung injury [202]. This poor treatment outcome, 
despite its efficient bactericidal activity, was attributed to rapid bacterial cell wall lysis 
and the release of copious amounts of bacterial PAMPs, including cell wall fragments, 
potentiating the inflammatory response in the co-infected lungs [204]. Trials in adults 
have demonstrated an improved cure rate for inpatient CAP treatment with either 
fluoroquinolone antibiotics or combination therapy with a β-lactam and a macrolide 
[217]. Our mouse studies suggest that, along with broadened coverage of atypical 
pathogens, the addition of the macrolide to the recommended treatment regimen reduces 
the inflammatory response by decreasing the massive influx of neutrophils and 
accompanying tissue damage characteristic of SBP [204]. However, treatment with 
antibiotics alone appears to still be sub-optimal in some patients and in these mouse 
models. 
 
 Due to their potent anti-inflammatory and diverse immunomodulatory activities, 
corticosteroids have been widely used to treat many inflammatory and immune diseases 
[218, 219]. However, the clinical use of corticosteroids as an adjunctive therapy for 
treating pneumonia has been controversial. Some randomized controlled clinical trials 
suggest beneficial activity in treating CAP with a significant reduction in the length of 
hospital stay [220, 221] or a decrease in mortality of patients with septic shock [222]. 
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However, others have shown no benefit or harmful outcomes [223, 224]. Based on these 
data and expert opinion, the World Health Organization (WHO) discouraged 
corticosteroid treatment during the 2009 influenza pandemic [225]. Collectively, there is 
not currently strong evidence in the literature for recommending adjunctive corticosteroid 
therapy. Nevertheless, steroids are often used in clinical practice, particularly in severe 
cases with acute lung injury, suggesting a need for further study [226-228]. 
 
 We hypothesized that adjunctive corticosteroid therapy would improve the poor 
outcomes associated with antibiotic treatment of SBP following influenza infection 
through modulation of inflammatory responses. We tested our hypothesis using a well-
established murine co-infection model in which we could monitor the progression of SBP 
in vivo [229]. To analyze the relationship between disease severity and outcomes, we 
categorized co-infected mice based on the lung bacterial load at the onset of antibiotic 
treatment to control for its impact on different treatment outcomes. We report here that 
dexamethasone therapy administered during the inflammatory period of severe SBP has a 
beneficial effect on outcomes. Early therapy, during primary influenza, is not beneficial 
and may enhance the infection by interfering with immune responses to the virus. 
 
 Additionally, we tested the efficacy of a novel immunomodulator drug, 2,3-
diacetyloxybenzoic acid (DABA). DABA was designed as a pro-drug of 2,3-
dihydroxybenzoic acid (DHBA) to increase its lipophilicity and thus increase its 
intracellular delivery [230]. DHBA is an old drug known by its strong iron chelation 
activity for a long time [231]. It was also identified as a siderophore secreted from some 
bacterial pathogens to facilitate iron uptake in the iron limited environment [232]. DHBA 
was shown to decrease vancomycin-induced nephrotoxicity in rats, which was assumed 
to be mediated through decreasing free hydroxyl radical formation [233]. 
 
 However, DHBA showed limited efficacy in treating animal models of acute lung 
injury and sepsis, whereas its pro-drug, DABA, was shown to attenuate the endotoxin-
induced acute lung injury in two separate animal models. Early systemic treatment by 
DABA before and after endotoxin administration could significantly decrease lung 
microvascular permeability [230]. Therefore, we sought to test if adjunctive DABA 
therapy would also prevent the increased lung immunopathology associated with 
antibiotic treatment of SBP. We also tested the efficacy of DABA with early 
administration during primary influenza infection. 
 
 
Materials and Methods 
 
 
Infectious Agents 
 
 PR8 influenza virus and S. pneumoniae A66.1, a type 3 encapsulated strain, were 
prepared and used for murine co-infections as described previously (pages 29 and 49). 
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Mice 
 
 Six- to 8-week-old female BALB/c mice (Jackson Laboratory, Bar Harbor, ME) 
were maintained in a Biosafety Level 2 facility in the Animal Resource Center at St. 
Jude. Animals were given general anesthesia that consisted of 2.5% inhaled isoflurane 
(Baxter Healthcare Corporation, Deerfield, IL) prior to all interventions, and all studies 
were approved by the Animal Care and Use Committee at St. Jude. 
 
 
Co-infection Model 
 
 Infectious agents were diluted in sterile PBS and administered intranasally in a 
volume of 100 μl (50 μl per nostril) to anesthetized mice held in an upright position. For 
primary influenza infection, influenza virus was given at a dose of 25 TCID50 per 100 µl 
per mouse, which caused about 10% weight loss on day 7 p.i (post infection) with no 
mortality when given alone. To engender SBP, influenza infection was followed on day 7 
p.i by bacterial challenge with 200 CFUs of pneumococcus per mouse. Infected mice 
were weighed and assessed daily for illness and mortality for 7 days after pneumococcal 
challenge; based on preliminary studies in this model and animal care considerations, any 
mouse losing more than 26% of its starting body weight was euthanized and considered 
to have died on that day. 
 
 
Imaging and Ampicillin Treatment of Live Co-infected Mice 
 
 Mice were imaged for 60 seconds using an IVIS CCD camera (Caliper Life 
Sciences, Alameda, CA) daily after pneumococcal challenge to monitor in vivo 
pneumococcal pneumonia development. Total photon emission from selected and defined 
areas within the images of each mouse was quantified using Living Image software 
(Caliper Life Sciences, Alameda, CA) as described previously [152, 203, 204], and 
expressed as the flux of relative light units per minute. Pneumonia was defined as visible 
bioluminescence within the thorax and detection of a flux of > 11,000 relative light units 
per minute (RLU/min) [229]. Based on previous studies that classified detection stage of 
SBP into early and late detection [152, 204], we assigned mild pneumonia to mice 
showing thorax bioluminescence and flux of more than 11,000 but less than 90,000 
RLU/min, while severe pneumonia was defined for mice with flux of more than 90,000 
RLU/min. Once SBP was detected, ampicillin (Sigma-Aldrich) was given i.p. as 200 
mg/kg/daily in two divided doses every 12 hours for 5 days.  
 
 
Flow Cytometric Analysis of Immune Cells in BALF and Post-lavage Lungs 
 
 Following euthanasia by CO2 inhalation, the trachea was exposed and cannulated 
with a 24-gauge plastic catheter (Becton Dickinson Infusion Therapy Systems, Inc., 
Sandy, UT). Lungs were lavaged, harvested, and homogenized as described previously 
(page 30). Then, cell suspensions of BALF and post-lavage lung homogenate were 
 62 
centrifuged at 4°C, 350 × g for 7 min. BALF and lung homogenate supernatants were 
stored at –80°C. Flow cytometry (LSRII, and LSRII Fortessa, Becton Dickinson, San 
Jose, CA) was performed on the cell pellets after incubation with Fc block (anti-mouse 
CD16/CD32, BD Bioscience Inc., San Jose, CAio), followed by surface marker staining 
with cocktail of anti-mouse antibodies conjugated with different fluorescent probes, 
including CD11c (eFluor 450), F4/80 (FITC), Ly6G (PerCp-Cy5.5), and CD11b (APC-
eFluor 780; eBioscience Inc., San Diego, CA), or CD3 (FITC), CD4 (APC), and CD8a 
(eFluor 450 or APC-eFluor 780; eBioscience Inc., San Diego, CA). FlowJo 8.8.6 (Tree 
Star, Ashland, OR) was used for data analysis, where viable cells were gated from an 
FSC/SSC plot, and then neutrophils were gated as (CD11b
hi
 Ly6G
hi
 CD11c
lo
 F4/80
lo
). T 
cells were gated as CD3
+
 SSC 
low-int
, followed by sub-gating of CD4
+
 CD8
-
 and CD8
+
 
CD4
-
 T cells subsets. Total viable cells were counted and absolute numbers of different 
cell types were calculated as described previously (page 30). 
 
 
Dexamethasone Treatment Regimen 
 
 Dexamethasone sodium phosphate injection solution (4 mg/ml; APP 
Pharmaceuticals, Schaumburg, IL) was diluted by sterile PBS solution to 0.5 mg/ml. In 
combined treatment experiments, dexamethasone dose (2.5 mg/kg/day) or vehicle (PBS) 
was given i.p. once daily 2-3 hours after ampicillin injection for 5 days as adjunctive 
therapy. In early treatment experiments, dexamethasone or PBS was given i.p. once daily 
starting from day 3 until day 13 after influenza infection. 
 
 
2,3-Diacetyloxybenzoic Acid Treatment Regimen 
 
 DABA was a kind gift from Dr. Ze-Qi Xu (Advanced Life Sciences Co., 
Woodridge, IL). DABA injection solution (25 mg/ml) was prepared freshly according to 
the manufacturer’s instructions. Briefly, 50 mg of the drug was dissolved in 0.5 ml of 
8.4% sodium bicarbonate injection, USP. Then, 1.5 ml of sterile distilled water was 
added followed by vortex and sonication until the drug powder gets completely 
dissolved, then the solution was filter sterilized. The injection solution was kept at 4°C 
and was used within 1-2 days. Mice were i.p injected with DABA in the same dose as 
used before for treating acute lung injury (150 mg/kg/day) [230], but following the same 
regimen as dexamethasone. 
 
 
Measurement of Viral Titers 
 
 Influenza viral titers were measured in the stored post-lavage lung homogenate 
supernatants by TCID50 assay in MDCK cells. 
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Measurement of Total Protein and Albumin Levels in BALF Supernatant 
 
 BALF supernatant aliquots were thawed and total proteins levels were measured 
spectrophotometrically using a NanoDrop 2000 Spectrophotometer (Thermo Fisher 
Scientific, Wilmington, DE). To measure albumin levels, BALF supernatant samples 
were diluted in sterile PBS, then albumin concentrations were measured using an ELISA 
kit (USCN Life Science Inc, Houston, TX). 
 
 
Statistical Analysis 
 
 Comparison of survival between groups of mice was done with the log-rank chi-
squared test on the Kaplan-Meier survival data. Means of relative bioluminescence units 
per minute were compared between groups using analysis of variance (ANOVA). 
Comparison of weight loss, immune cells numbers, or viral titers between groups of mice 
was done using Mann-Whitney U test for pair-wise comparisons. A p-value of < 0.05 
was considered significant for these comparisons. Prism 4 for Windows (GraphPad 
Software, Inc., V 4.03) was used for all statistical analyses. 
 
 
Results 
 
 
Ampicillin Treatment during Secondary Pneumococcal Pneumonia Fails to Rescue 
Mice Despite Viral and Bacterial Clearance 
 
To engender SBP, naïve BALB/c mice were intranasally infected by a sublethal 
dose of influenza virus, followed by a small inoculum of pneumococcus on day 7 after 
influenza infection (Figure 4-1A). Within 48 h after bacterial inoculation, co-infected 
mice developed SBP that could be detected in vivo by bioluminescence imaging. Without 
treatment all co-infected mice succumbed to bacterial pneumonia within a few days 
(Figure 4-1B). To confirm the poor efficacy of a standard antibiotic treatment in rescuing 
mice with SBP, I started ampicillin treatment upon pneumonia detection via 
bioluminescence (Figure 4-1A and C). As seen previously [202, 204, 234], ampicillin 
could only rescue about 40% of pneumonic mice (Figure 1B), despite rapid declines in 
bacterial burden within 12 h after the first dose of ampicillin (Figure 4-1C and D). Viral 
titers were undetectable in the alveolar airspaces 24 h after the first ampicillin dose (data 
not shown). 
 
 
Differential Outcomes Depend on the Severity of Secondary Pneumococcal 
Pneumonia at the Onset of Antibiotic Treatment 
 
To determine if the severity of SBP at the onset of antibiotic treatment affects 
treatment outcomes, we classified the severity of pneumonic mice prior to antibiotic 
treatment into mild or severe pneumonia. This classification was based on the  
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Figure ‎4-1. Ampicillin treatment of secondary pneumococcal pneumonia 
 
(A) Diagram showing the co-infection model where mice are intranasally infected by 
influenza virus (PR8) followed by secondary pneumococcal challenge (S. pneumoniae) 7 
days later. The ampicillin treatment regimen is started upon secondary pneumococcal 
pneumonia detection (often on day 9 p.i). (B) Survival rates of co-infected mice either 
untreated (n = 6) or after ampicillin treatment (n = 17). (C) Two representative 
bioluminescent images of co-infected mice showing development of secondary 
pneumococcal pneumonia (0 h), and effective pneumococcal killing 12 h after first 
ampicillin dose. (D) Significant reduction of throax bioluminescence flux from mice with 
secondary pneumococcal pneumonia (n = 8) after first doses of ampicillin treatment to 
levels comparable to naïve mice (n = 6, measurements expressed as relative luminescence 
units (RLU)/min). 
*P < 0.05 by log-rank test on the Kaplan–Meier survival data, compared with untreated 
group (Panel B). ***P < 0.001 by ANOVA test, compared with all other groups (Panel 
D). The bar graph shows the average ± SD. 
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pneumococcal load in co-infected lungs, as monitored through bioluminescence imaging 
as defined in the methods (Figure 4-2A). 
 
 Ampicillin treatment was associated with disparate mortality outcomes in mice 
with different degrees of pneumonia at the onset of treatment (Figure 4-2B). All 
ampicillin-treated mice with severe pneumonia succumbed to pneumonia in a similar 
pattern to that of the untreated group. In contrast, more than 60% of ampicillin-treated 
mice with mild pneumonia were rescued (Figure 4-2B). These differential mortality 
outcomes after ampicillin treatment were not due to lack of ampicillin bactericidal 
activity in mice with severe pneumonia; the first ampicillin dose demonstrated in vivo 
efficacy with rapid bacterial killing, reflected by the significant decrease in 
bioluminescence signals to levels comparable to uninfected mice, in a similar pattern to 
ampicillin-treated mice with mild pneumonia (Figure 4-2C). 
 
 However, differential accumulation of neutrophils was observed within the 
alveolar airspaces of mildly and severely pneumonic mice 26 h after the first ampicillin 
dose (Figure 4-3A). Interestingly, ampicillin treatment of mice with severe SBP induced 
significantly greater accumulation of neutrophils than in the untreated mice with SBP at 
the same time point (day 10 after influenza infection) (Figure 4-3A). Furthermore, 
significantly higher total proteins levels were detected in the BALF supernatant of 
ampicillin-treated mice with severe pneumonia (Figure 4-3B). 
 
 
Adjunctive Dexamethasone Treatment Rescues Ampicillin-treated Mice with Severe 
Secondary Pneumococcal Pneumonia 
 
 Since treatment by ampicillin alone failed to rescue mice with severe pneumonia, 
despite its efficient bactericidal activity, we hypothesized that an anti-inflammatory agent 
could dampen the associated inflammatory responses and improve outcomes. Adjunctive 
dexamethasone therapy significantly improved the survival rate, rescuing about 70% of 
mice with severe pneumonia (Figure 4-4A). Mice with mild pneumonia also 
demonstrated a modest increase in survival that was not statistically significant after 
adjunctive dexamethasone treatment, but suffered morbidity reflected by significant delay 
in regaining their body weight as compared to the PBS and ampicillin-treated control 
group (Figure 4-4B). Improved outcomes with combined therapy were associated with 
significantly decreased neutrophil accumulation after the second dose (Figure 4-5A) and 
significantly reduced serum albumin leakage into alveolar airspaces after the first dose 
(Figure 4-5B). 
 
 
Early Dexamethasone Treatment Leads to Loss of Its Protective Activity 
 
 To test if dexamethasone administration early after influenza infection can 
enhance its protective activity and increase survival of ampicillin-treated pneumonic 
mice, we started dexamethasone or PBS treatment 3 days after influenza infection and 
continued thereafter until day 13 p.i using the same co-infection model. As before,  
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Figure ‎4-2. Differential mortality outcomes depend on the severity of secondary 
pneumococcal pneumonia at the onset of antibiotic treatment  
 
(A) Representative images showing bioluminescence measurements from two different 
co-infected mice with mild or severe secondary pneumococcal pneumonia. Images were 
taken 48 h after secondary pneumococcal challenge and prior to ampicillin treatment. (B) 
Survival rates of co-infected mice with mild (Amp-M, n = 10) or severe (Amp-S, n = 7) 
secondary pneumococcal pneumonia treated with ampicillin. (C) Significant reduction in 
thorax bioluminescence flux from co-infected mice with either mild or severe secondary 
pneumococcal pneumonia after first doses of ampicillin treatment (n = 10) to levels 
comparable to naïve mice (n = 6). 
** P < 0.01 by log-rank test on the Kaplan–Meier survival data, compared with Amp-S 
group (Panel B), *** P < 0.001 by ANOVA test, compared with all other groups (Panel 
C). The bar graphs show the average ± SD. 
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Figure ‎4-3. Differential lung immunopathology depends on the severity of 
secondary pneumococcal pneumonia at the onset of antibiotic treatment 
 
(A) Absolute numbers of neutrophils in BALF of mock-infected (naïve, white-filled, n = 
12), untreated co-infected mice on day 10 after influenza infection (black-filled, n = 15), 
or ampicillin-treated mice with mild (light gray-filled, n = 7) or severe (dark gray-filled, n 
= 6) secondary pneumococcal pneumonia 3 days after bacterial challenge (i.e. 26 h after 
first ampicillin dose). (B) Total proteins levels in BALF supernatant of untreated co-
infected mice on day 10 after influenza infection (black-filled, n = 5), ampicillin-treated 
mice with mild (light gray-filled, n = 7) or severe (dark gray-filled, n = 9) pneumonia, 
measured 26 h after first ampicillin dose. 
* P < 0.05, *** P < 0.001 by ANOVA test, compared with all other groups (Panel A and 
B). The bar graphs show the average ± SD. 
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Figure ‎4-4. Adjunctive dexamethasone treatment rescues ampicillin-treated mice 
with severe secondary pneumococcal pneumonia 
 
Survival rates and body weight loss curves of ampicillin-treated mice with either severe 
(Panel A, n ≥ 7) or mild (Panel B, n ≥ 9) secondary pneumococcal pneumonia with 
adjunctive dexamethasone or mock (PBS) therapy.  
*P < 0.05,** P < 0.01 compared with adjunctive PBS therapy group by log-rank test on 
the Kaplan–Meier survival data (Panel A), or Mann-Whitney U test for body weight loss 
curve (Panel B). Data are expressed as the average ± SEM. 
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Figure ‎4-5. Adjunctive dexamethasone therapy improves lung inflammation and 
pulmonary vascular permeability in mice with severe secondary pneumococcal 
pneumonia 
 
(A) Absolute numbers of neutrophils within alveolar airspaces of mice with severe 
secondary pneumococcal pneumonia, measured 26 h after the first or second dose of 
dexamethasone (white-filled, n = 4 or 3, respectively) or mock therapy (dark gray-filled, 
n = 6 or 5, respectively) combined with ampicillin treatment. (B) Albumin levels in 
BALF supernatant harvested from mice with severe secondary pneumococcal pneumonia 
26 h after the first or second dose of adjunctive dexamethasone (white-filled, n = 4 or 3, 
respectively) or mock therapy (dark gray-filled, n = 6 at both time points) combined with 
ampicillin treatment. 
*P < 0.05 by Mann-Whitney U test. The bar graphs show the average ± SD. 
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ampicillin treatment was initiated upon detection of SBP. Interestingly, early 
dexamethasone treatment did not augment the survival improvement of ampicillin-treated 
pneumonic mice; rather, it led to loss of its protective activity (Figure 4-6A). Survival of 
ampicillin-treated mice with severe pneumonia dropped from about 70% with adjunctive 
dexamethasone therapy (Figure 4-4A) to about 30% with early dexamethasone regimen 
(Figure 4-6A). Furthermore, ampicillin-treated mice with mild pneumonia demonstrated 
a modest, non-significant increase in mortality after early dexamethasone treatment as 
compared to mock-treated group (Figure 4-6A). In addition, similar to the poor 
morbidity outcome of adjunctive therapy in mice with mild pneumonia, early 
dexamethasone treatment was associated with increased body weight loss from primary 
influenza and delayed body weight regain after ampicillin treatment of SBP (Figure 
4-6B). 
 
 
Early Dexamethasone Treatment Suppresses Adaptive Immunity 
 
Glucocorticoids are known to suppress adaptive immunity [235]. Therefore, we 
hypothesized that the increased morbidity associated with early dexamethasone therapy 
during primary influenza infection was due to suppressed adaptive immunity, leading to 
elevated influenza viral titers and increased lung injury. We measured the numbers of T 
cells in both BALF and post-lavage lungs on day 7 after influenza infection under early 
dexamethasone or mock treatment (i.e., 24 h after the fourth dose of dexamethasone or 
PBS). As expected, early dexamethasone treatment significantly reduced the absolute 
numbers of CD4
+
 and CD8
+
 T cells in lungs as compared to mock treatment (Figure 
4-7A). To determine if this reduction in the respiratory pool of T-cells was associated 
with impaired influenza viral clearance, we measured influenza viral titers on day 7 p.i. 
Early dexamethasone-treated mice had significantly higher influenza viral titers than 
mock-treated mice (Figure 4-7B). 
 
 
Adjunctive DABA Treatment Improves Survival of Ampicillin-treated Mice with 
Secondary Pneumococcal Pneumonia 
 
 The findings that adjunctive dexamethasone therapy worsened the morbidity of 
ampicillin-treated mice with mild SBP, reflected by the delayed body weight regain 
(Figure 4-4B), put the proposed use of dexamethasone into question. Therefore, we 
tested the efficacy of a novel immunomodulator drug, DABA, for treating SBP using the 
same treatment regimen as dexamethasone. We found that adjunctive DABA therapy 
improved survival of ampicillin-treated mice with severe or mild SBP in a rate similar to 
that of adjunctive dexamethasone treatment. Combined DABA plus ampicillin treatment 
could significantly increase the survival rate of mice with severe SBP from 0% to about 
70%. In addition, adjunctive DABA therapy could rescue all ampicillin-treated mice with 
mild SBP, but the increase in the survival rate was not statistically significant compared 
to the mice group subjected to mock adjunctive therapy (Figure 4-8A and B). 
 
 In contrast to dexamethasone treatment, adjunctive DABA therapy did not worsen  
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Figure ‎4-6. Early dexamethasone treatment leads to loss of its protective activity 
 
(A) Survival rates of co-infected mice with early dexamethasone or mock (PBS) therapy 
started during primary influenza infection, and continued with ampicillin treatment after 
detection of severe (Early Dexa-S, n = 7 or Early PBS-S, n = 5 respectively) or mild 
(Early Dexa-M, n = 9 or Early PBS-M, n = 9, respectively) secondary pneumococcal 
pneumonia. (B) Body weight loss curve of influenza-infected mice with early 
dexamethasone or mock (PBS) therapy, challenged with bacteria on day 7 p.i, and treated 
later with ampicillin after detection of mild secondary pneumococcal pneumonia (n = 9).  
*P < 0.05,** P < 0.01 by Mann-Whitney U test (Panel B). Data are expressed as the 
average ± SEM. 
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Figure ‎4-7. Early dexamethasone treatment suppresses adaptive immunity 
 
(A) Absolute numbers of CD4
+
 and CD8
+
 T cells within alveolar airspaces (BALF), or in 
post-lavage lungs of influenza-infected mice measured on day 7 p.i with early 
dexamethasone or mock (PBS) therapy (n = 4 or 5, respectively). (B) Influenza viral titers 
in post-lavage lungs of influenza-infected mice measured on day 7 p.i with early 
dexamethasone or mock (PBS) therapy (n = 4 or 5, respectively). 
*P < 0.05 by Mann-Whitney U test. The bar graphs show the average ± SD. 
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Figure ‎4-8. Adjunctive 2,3-diacetyloxybenzoic acid treatment improves survival 
of ampicillin-treated mice with secondary pneumococcal pneumonia 
 
Survival rates and body weight loss curves of ampicillin-treated mice with either severe 
(Panel A, n = 7 for each group) or mild (Panel B, n ≥ 8 for each group) secondary 
pneumococcal pneumonia with adjunctive 2,3-diacetyloxybenzoic acid (DABA) or mock 
(PBS)
*
 therapy. (C) Absolute numbers of neutrophils within alveolar airspaces of mice 
with severe secondary pneumococcal pneumonia, measured 26 h after the first  or second 
dose of adjunctive DABA (red-filled, n = 5 or 3, respectively) or mock therapy (dark 
gray-filled, n = 6 or 5, respectively) combined with ampicillin treatment. 
** P < 0.01 by log-rank test on the Kaplan–Meier survival data, *P < 0.05 by Mann-
Whitney U test (Panel C). Data are expressed as the average ± SEM (Panel A and B), or 
as the average ± SD (Panel C). 
*
I used the same mock-treated groups in (Figure 4-4), as I used different drug treatment 
in the same experimental setting. 
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the morbidity of ampicillin-treated mice with mild SBP. This was implicated by 
monitoring the body weight recovery of mice with mild SBP, as DABA-treated mice 
showed comparable rate of body weight regain to the mice group with adjunctive mock 
therapy (Figure 4-8A and B). Improved survival with combined DABA therapy of mice 
with severe SBP was accompanied by significantly decreased neutrophil accumulation 
after the second dose (Figure 4-8C). 
 
 
Early DABA Treatment Does Not Worsen the Morbidity of Influenza-infected Mice 
 
 Another caveat of dexamethasone use that was revealed in our model of SBP is 
the significant impact of changing its administration timing. We demonstrated that early 
dexamethasone therapy during the primary influenza infection had a negative impact on 
the course of influenza infection and was associated with increased morbidity of 
influenza-infected mice. Therefore, we sought to test if early DABA treatment would 
have similar bad outcomes as early dexamethasone therapy. Early DABA treatment was 
initiated from day 3 until day 13 after influenza infection, while ampicillin treatment was 
given upon detecting SBP. Early DABA treatment did not worsen the morbidity of 
influenza-infected mice (Figure 4-9B). Nonetheless, early DABA therapy showed partial 
loss of their protective activity against mortality of ampicillin-treated mice with severe 
SBP (Figure 4-9A), in a pattern similar to that of early dexamethasone therapy. 
 
 
Discussion 
 
Historically, death from SBP was a common feature of all influenza pandemics in 
the pre-antibiotic era [123]. Indeed, mortality from pneumococcal pneumonia 
significantly decreased after the discovery of penicillin [236]. Nevertheless, SBP still 
contributes significantly to morbidity and mortality during seasonal influenza and recent 
influenza pandemics, despite the use of effective antibiotics [214]. Furthermore, rates of 
mortality due to pneumococcal pneumonia have been relatively stable throughout the 
antibiotic era even with the routine use of more advanced β-lactam antibiotics [237, 238]. 
In a similar pattern, ampicillin treatment of SBP in our murine model demonstrated 
therapeutic failure here and in previous studies [202, 204, 234]. Despite its effective rapid 
bactericidal activity and significant pneumococcal clearance, ampicillin therapy failed to 
rescue more than 50% of mice with SBP. This has been previously attributed to rapid 
bacterial cell wall lysis, accompanied by release of bacterial cell wall fragments 
activating exuberant inflammatory responses in lungs, thereby leading to increased 
morbidity and mortality [204]. 
 
As the degree of severity of SBP may affect ampicillin treatment outcomes, we 
determined pneumococcal load in vivo using a sensitive non-invasive bioluminescence 
imaging to approximate pneumococcal outgrowth in the co-infected lungs prior to 
treatment, then classified SBP into mild or severe based on this surrogate for 
pneumococcal load. Interestingly, ampicillin treatment caused disparate mortality rates in 
mice with different degrees of pre-treatment severity of SBP. This finding suggests 
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Figure ‎4-9. Early 2,3-diacetyloxybenzoic acid treatment does not worsen 
morbidity of influenza-infected mice 
 
(A) Survival rates of co-infected mice with early 2,3-diacetyloxybenzoic acid (DABA) or 
mock (PBS)
*
 therapy started during primary influenza infection, and continued with 
ampicillin treatment after detection of severe (Early DABA-S, n = 4 or Early PBS-S, n = 
5) or mild (n = 9 for each group) secondary pneumococcal pneumonia. (B) Body weight 
loss curve of influenza-infected mice with early DABA or mock therapy, challenged with 
bacteria on day 7 p.i, and treated later with ampicillin after detection of mild secondary 
pneumococcal pneumonia (n = 9). Data are expressed as the average ± SEM. 
*
I used the same mock-treated groups in (Figure 4-6), as I used different drug treatment 
in the same experimental setting. 
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a direct correlation between pneumococcal load size at the onset of antibiotic therapy and 
the poor survival outcomes during antibiotic treatment of SBP. This relationship was 
inferred through modulating the degree of lung immunopathology induced after bacterial 
cell lysis with ampicillin. Thus, ampicillin treatment of mice with severe SBP aggravated 
lung immunopathology compared to those with mild SBP. Yet, both groups of mice 
showed comparable rapid pneumococcal clearance after the first two doses of ampicillin. 
The differential ampicillin treatment-associated immunopathology was evident on the 
second day of treatment, when mice with severe SBP had significantly increased 
accumulation of neutrophils within the alveolar airspaces, and increased pulmonary 
vascular permeability compared to ampicillin-treated mice with mild SBP. 
 
 To protect against the lung immunopathology induced during antibiotic treatment 
of SBP, we used the standard anti-inflammatory drug dexamethasone, which is well 
known for its potent inflammatory suppressive and immunomodulatory activities. 
Dexamethasone is one of the synthetic corticosteroids that are clinically used to treat 
several inflammatory disorders and autoimmune diseases [219]. However, the benefits of 
adjunctive corticosteroid therapy of CAP have been under debate for a long time [227, 
239] due to conflicting results from different studies of this potential therapy [220, 221, 
223, 224, 240-242]. In our murine model of SBP, adjunctive dexamethasone treatment 
improved survival rates of pneumonic mice. Interestingly, best results were observed in 
ampicillin-treated mice with severe SBP, in which treatment-associated 
immunopathology was significantly attenuated. This was achieved after the second dose 
of dexamethasone, where accumulation of neutrophils within the alveolar airspaces was 
significantly reduced compared to mock plus ampicillin-treated mice. Furthermore, a 
significant decrease in pulmonary vascular permeability was observed one day after the 
first dose of dexamethasone. These treatment outcomes of severe SBP in our murine 
model are consistent with several randomized controlled trials that showed that the 
beneficial outcomes of adjunctive corticosteroids therapy are limited to severe cases of 
community-acquired pneumonia in humans [220, 221, 241, 242]. We used 
dexamethasone at a dose (2.5 mg/kg) that was previously shown to suppress the 
pulmonary inflammatory responses in various murine models of airway inflammation, 
such as endotoxin-induced acute lung injury, house dust-induced asthma, and allergic 
bronchopulmonary aspergillosis [243-245]. Other researchers have shown that 
dexamethasone treatment from days 3-14 after highly pathogenic avian influenza 
infection had no beneficial effect on acute respiratory distress syndrome caused by the 
H5N1 infection in mice [246], data which support our findings regarding the poor 
outcomes associated with early dexamethasone treatment during primary influenza 
infection. Additionally, our dose of dexamethasone is clinically relevant to the 
corticosteroid doses, which showed beneficial outcomes as adjunctive therapy of adult 
humans with severe CAP [247-249]. 
 
 However, corticosteroids have potential drawbacks, as they can cause systemic 
immunosuppression [219, 235]. Therefore, we tested the effect of early administration of 
dexamethasone during primary influenza infection to determine whether it would remain 
beneficial in ampicillin-treated mice with severe SBP. As expected, early dexamethasone 
treatment significantly decreased numbers of both CD8
+
 and CD4
+
 T cells in the lungs on 
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day 7 after influenza infection. This was associated with delayed influenza viral clearance 
and accelerated morbidity progression during primary influenza infection and before 
secondary pneumococcal challenge. This had a negative impact on ampicillin treatment-
associated fatality with eventual loss of the protective functions of the adjunctive 
dexamethasone regimen in mice with either mild or severe SBP. 
 
 Therefore, we tested the efficacy of another novel immunomodulator drug – 
DABA that could effectively attenuate the endotoxin-induced acute lung injury in 2 
different animal models by decreasing the pulmonary vascular permeability. Adjunctive 
DABA therapy improved survival of ampicillin-treated mice with SBP, with more 
pronounced effect on mice with severe SBP associated with significant decrease in 
neutrophil accumulation within the alveolar airspaces. Additionally, DABA did not 
worsen the morbidity of mice with mild SBP. Furthermore, early DABA therapy during 
influenza infection did not have detrimental effect on the morbidity of influenza-infected 
mice. Nevertheless, early DABA therapy did not augment the improved survival of 
adjunctive DABA-treated mice, but rather it led to a partial loss of its protective 
functions.  
 
 Taken together, our data suggest that the general unrestricted use of adjunctive 
corticosteroid therapy during influenza or CAP is likely not warranted. Several factors 
may participate in balancing the beneficial and detrimental outcomes after systemic 
corticosteroid treatment, such as the drug dose, the onset and duration of treatment, the 
causative infectious agents, and whether the pneumonia is caused by a single bacterial or 
viral agent or is due to a co-infection. Our findings demonstrate that the bacterial burden 
during pneumonia has an impact on treatment outcomes with larger burdens generating 
more inflammation and higher mortality upon antibiotic-mediated lysis. Furthermore, 
these experiments support the observed preferential beneficial activity of corticosteroids 
when combined with antibiotic treatment in severe cases of CAP. Interestingly, our data 
point out a significant impact of the timing of dexamethasone therapy on its protective 
functions, which would be of great importance in modifying treatment protocols of 
severe cases of SBP following viral infections. Thus, our experiments suggest that early 
corticosteroid administration during primary influenza infection can worsen adaptive 
immunity against influenza infection, thereby increasing viral titers and consequently 
increasing viral-mediated lung damage. Late treatment with steroids, when virus has 
cleared and inflammation is driving disease, can improve outcomes. Additionally, our 
preliminary experiments on adjunctive DABA therapy showed promising results for 
treating CAP without detrimental impact on mild cases. However, it would be interesting 
to investigate the mechanism of action of DABA treatment in the context of antibiotic 
therapy of SBP, which may promote its clinical use during treatment of CAP. Finally, our 
study further advances an animal model with sophisticated tools for classifying the 
severity of bacterial pneumonia, which will help investigating the efficacy of different 
immunomodulators as adjunctive therapy, as well as different or new classes of 
antibiotics for treatment of SBP. 
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CHAPTER 5.    GENERAL DISCUSSION, INSIGHTS, AND FUTURE 
DIRECTIONS 
 
 
 Bacterial super-infections have been implicated to mediate the increased 
morbidity and deaths during influenza pandemics, epidemics, and even seasonal 
influenza, with consequent tremendous socioeconomic burden [36, 120]. Their great 
clinical impact was initially observed long ago, when a French physician, René Laennec, 
observed the increased frequency of “double” pneumonia as a fatal complication during 
an influenza epidemic in 1803 [121]. Later, during the 1918 influenza pandemic, many 
investigators also pointed out the significant contribution of SBP in causing the most 
deaths in an event that exceeded 30 million fatal cases worldwide. Even though the 
discovery of penicillin and other antibiotics led to a significant reduction in the mortality 
rate due to SBP, bacterial super-infections remained a serious medical problem during 
influenza outbreaks and pandemics, such as the 1957, 1968, and 2009 influenza 
pandemics [35]. 
 
 S. pneumoniae is the predominant secondary bacterial pathogen during influenza 
infections. Because of its nasopharyngeal colonization in some asymptomatic carriers, 
pneumococcus can easily spread among influenza-infected patients via respiratory 
droplet inhalation. However, unique lethal synergism has been observed between primary 
influenza infections and secondary pneumococcal infections. 
 
 Although many investigators have established the respiratory viral-bacterial 
synergism in animal models, the mechanisms underlying it are still unclear. A complete 
understanding of this synergism was hindered by the commonly believed concept of 
influenza-induced epithelial damage as the major predisposing factor to secondary 
bacterial infections. Indeed, some influenza viral virulence factors displayed important 
roles in this synergism. However, these factors are basically critical for viral 
pathogenesis, which is a prerequisite for secondary bacterial infections. Thus, this 
concept would be valid for highly virulent influenza virus strains. However, the findings 
that even mild seasonal influenza viruses can also enhance the vulnerability to secondary 
bacterial infections have suggested the existence of more critical mechanisms for this 
unique synergism drawing the attention to explore possible alterations of the host 
immunity during influenza infections. 
 
 Alterations in host immunity have become an increasingly important aspect of the 
influenza-mediated predisposition to SBP. Among numerous alterations in host immune 
responses during influenza infections, defects in pulmonary antibacterial immunity have 
been observed explaining the strikingly increased vulnerability to bacterial infections. 
Recently, several mechanisms of the defects in various antibacterial immune effectors 
have been proposed in influenza-infected lungs [147]. Among those immune effectors, 
resident AMs play a central role in effective protection against bacterial pathogens in the 
lungs. 
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Impact of Influenza Infections on Resident Alveolar Macrophages In Vivo 
 
 Early studies in the 20
th
 century indicated defective phagocytic functions of AMs 
during mild and severe influenza infections. [145-148]. Recently, it’s been suggested that 
the AM dysfunction during influenza infections is due to IFNγ-induced downregulation 
of the expression of MARCO receptor [101], a scavenger receptor on the surface of AMs, 
which was implicated in non-opsonized phagocytosis of pneumococci [97]. They 
proposed this mechanism of defective phagocytosis of AMs only when IFNγ secretion is 
significantly elevated in the lungs, which is temporally related to adaptive immune cell 
accumulation during the resolution phase of sublethal influenza infection [101, 150]. 
However, this mechanism fails to explain the common clinical observations and studies 
on animal models of bacterial co-infections that showed increased predisposition to 
secondary bacterial infections during the first week of influenza, even before the 
appearance of adaptive immune cells and the peak of IFNγ production. In addition, 
another study showed that augmented IFNγ production in the lungs can provide 
protective activity, possibly by increasing neutrophil influx, against lethal pneumococcal 
pneumonia [205]. 
 
 Despite the repeated investigation of influenza infection impact on resident AMs, 
the results were confounding, because most studies were performed using in vitro 
infection systems, which may not be pathologically relevant to the in vivo influenza 
infections due to differences in the microenvironment conditions [47, 48, 51]. Even 
though some investigators have studied the alterations of AM functions in vivo, the 
misrepresentation of resident AM subset by the total macrophage population harvested in 
BAL during influenza infections, without strict discrimination approaches, may lead to 
profoundly erroneous conclusions about the actual state of resident AMs. As a part of the 
innate immune responses to influenza infections, circulating macrophages and monocytes 
are recruited to and accumulate in influenza-infected lungs. Therefore, macrophages 
isolated by BAL process would represent heterogeneous populations of macrophages 
with different phenotypes. Thus, some investigators implied no change or a significant 
increase in the numbers of AMs associated with functional phenotype changes during in 
vivo influenza infections [101, 185]. 
 
 In contrast, I argue that most of these studies showed erroneous conclusions about 
the mechanistic influence of influenza infection on resident AMs due to the lack of 
approaches discriminating resident AMs from the recruited exudate inflammatory 
macrophages during influenza infection. Thereby, these technical limitations have 
hindered clear understanding of mechanisms underlying the defects in their protective 
functions during influenza infections. 
 
 To determine the impact of sublethal influenza infection on resident AMs in vivo, 
I initially characterized different lung-resident macrophage subsets using flow cytometry 
analyses coupled with a quite novel in vivo labeling approach through intranasal 
administration of the fluorescent PKH26-PCL dye. This in vivo labeling technique 
selectively labeled lung-resident macrophages with efficient stability for more than 2 
weeks. Comparisons of the fluorescence intensity of the intracellular PKH26-PCL dye 
 80 
facilitated successful discrimination between the two major subsets of lung-resident 
macrophages – AMs and IMs, and could clearly distinguish them from all myeloid 
subsets recruited during influenza infection. 
 
 Surprisingly, I found that sublethal influenza infections using the mouse-adapted 
PR8 influenza or a human clinical isolate of 2009 pandemic H1N1 influenza virus strains 
caused significant depletion of resident AMs, but not IMs, with a maximum nadir on day 
7 after influenza infection. AM depletion was temporally aligned with the impaired early 
pneumococcal clearance within the alveolar airspaces from day 3 to day 9 after influenza 
infection. Later, the AM pool was fully replenished leading to recovery of antibacterial 
immunity in the lungs. Synergistic interaction between primary influenza and secondary 
pneumococcal infections was successfully implemented during AM depletion phase, 
reflected by the progression of lethal secondary pneumococcal pneumonia. 
 
 What suggested the causal relationship between AM depletion and increased 
permissiveness to SBP are the protective outcomes of the immunomodulation approach 
that we used to expand the pool size of resident AMs during influenza infection. Local 
pulmonary GM-CSF treatment could significantly expand the pool size of IMs with 
partial expansion of AMs during influenza infection. These effects could partially restore 
the protective early bacterial clearance in the lungs and protected co-infected mice 
against development of SBP. 
 
 
Insights 
 
 Because of their unique anatomical position at the interface between air and 
alveolar epithelial cells and continuous exposure to the external environment, resident 
AMs have a pivotal role for maintaining protection in the lungs against inhaled noxious 
agents, including environmental particles and bacterial pathogens. Their functions rely on 
two unique features: high phagocytic capacity and immunosuppressive nature. Therefore, 
pathological AM depletion during mild influenza infections would have several 
consequences on the innate and adaptive immune responses in the lungs. 
 
 We examined the first obvious consequence of AM depletion during influenza 
infections which is the expected defect in the first line of pulmonary innate immunity 
protecting against bacterial pathogens. Indeed, the early bacterial clearance was notably 
impaired during the AM depletion phase. Pulmonary phagocytic capacity was carefully 
tested using small inocula of pneumococci rather than big inocula that were used in 
almost all animal models of secondary bacterial infections following influenza. The use 
of relatively big inocula of pneumococci for studying protective functions of resident 
AMs is considered a critical limitation in these animal studies, because these big inocula 
bypass the phagocytic threshold of resident AMs, and perhaps they are not relevant to 
clinical settings. In addition, in some studies bacterial clearance was examined at later 
time points, such as 24 and 48 h after bacterial inoculation, when neutrophils accumulate 
as the second line of innate defense. Thereby, they ended up studying neutrophil 
functions rather than that of resident AMs. 
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 Consequently, lethal SBP was successfully developed if influenza-infected mice 
were secondarily infected by small inocula of pneumococci during the AM depletion 
phase. Taken together, the novel finding of AM depletion during influenza infection 
implied a novel potential mechanism of the pulmonary viral-bacterial synergism which 
coincides with the order and timings of SBP in humans [198]. In addition, this 
mechanism may sound more reasonable to explain the increased vulnerability of 
influenza-infected hosts to different multiple bacterial pathogens, instead of specific 
viral-bacterial interactions. 
 
 Indeed, two recent studies confirmed our data using completely different, yet 
elegant, approaches. In the first study, the research group used mice with genetically 
engineered fluorescent reporter in tissue-resident macrophages, including AMs. They 
demonstrated dramatic cytoablation of lung-resident macrophages 6 days after sublethal 
PR8 influenza infection [173]. Furthermore, they also showed that most of the recovery 
of lung-resident macrophage, after diphtheria toxin-induced depletion, was achieved by 
stochastic local cellular proliferation in a macrophage colony-stimulating factor (M-
CSF)- and GM-CSF-dependent manner but independently of IL-4 [173]. These data 
correlate with our findings about the ontogeny of replenished AMs after influenza 
infection, which we proposed to be achieved by local proliferation of labeled IMs and 
their maturation into resident AM phenotype (Figure 2-9). 
 
 Additionally, a recent study using mathematical modeling of bacterial co-
infection, with the same infectious agents as in our model, expected significant loss of 
about 90% of AM functions by day 7 after sublethal PR8 influenza infection [250]. We 
experimentally demonstrated the same results with depletion of about 90% of resident 
AMs on day 7 after sublethal PR8 influenza infection. Furthermore, they hypothesized 
that this AM dysfunction is one of the major mechanisms underlying the increased 
influenza-pneumococcal co-infection synergism supporting our experimental data [250]. 
 
 There may also be other effects of AM depletion during influenza infections, 
which may not be related to their phagocytic functions, rather stem from their 
immunosuppressive activities demonstrated in several in vitro and in vivo studies. They 
display poor antigen presenting abilities and consequently poor T cell stimulation, as well 
as inhibitory effects on local DC functions [175-178]. Recently, lung-resident 
macrophages were shown to be critical mediators of the airway immune tolerance 
through inducing the generation of Foxp3
+
 regulatory T cells in a TGF-β- and retinoic 
acid-dependent manner [251]. Indeed, artificial depletion of pulmonary macrophages 
using clodronate liposomes abrogated the immunosuppressive state while augmented 
adaptive immune responses in the lungs [252]. In addition, their artificial depletion was 
shown to increase secondary IgE responses and infiltration of B cells and T cells into the 
lungs after allergen exposure [253], as well as increase NK cells and functionality of 
CD4
+
 and CD8
+
 T cells during respiratory pneumovirus infection in mice [254]. 
Furthermore, a recent study using a murine model of ovalbumin-induced acute asthma 
demonstrated that clodronate-mediated depletion of AMs increased the airway infiltration 
of inflammatory immune cells, eosinophils and lymphocytes as well [255]. In contrast, 
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the allergic airway inflammation and hyperresponsiveness were attenuated after adoptive 
transfer of naive AMs [255, 256]. However, liposome-encapsulated clodronate may also 
induce depletion of IMs along with AMs, which may complicate the results, as IMs have 
stronger antigen presenting abilities and stimulatory functions than AMs. In contrast, 
pathological depletion of AM subset alone may have even more profound impact on the 
adaptive immune responses and allergic reactions in influenza-infected lungs.  
 
 Based on the kinetics of the adaptive immune responses during influenza 
infections, the peak of their cellular effectors recruitment and functionality in the lungs is 
quite coincident with the nadir of AM depletion at the end of the first week of influenza 
infection. This correlation may give novel insights about a probable role of AM depletion 
in releasing the immunosuppressive brakes in the lungs. Thereby, allowing an efficient 
functionality of influenza-specific adaptive immune cells in the lungs. 
 
 Among other probable outcomes of AM depletion during influenza infections is 
the influence on the progression of airway hypersensitivity and asthma by possibly 
lowering the activation threshold for allergen-specific immune cells. Indeed, influenza 
infections in infants have been recognized as a potent risk factor for asthma development 
later. Furthermore, asthma exacerbation has been well documented during seasonal and 
pandemic influenza infections and other respiratory viral infections [55, 257, 258]. In 
addition, a recent study, in an infant mouse allergy model using house dust mite, 
demonstrated exacerbation of airway allergic responses when they get infected by 
influenza viruses [259]. Yet, the mechanisms underlying this synergism have not been 
completely elucidated. 
 
 
Future Directions 
 
 The question of how influenza viruses cause depletion of resident AMs in vivo 
still needs to be fully answered. Indeed, some previous studies showed direct influenza 
infection of AMs, followed by apoptosis [260, 261]. However, infection was observed in 
only a small percentage of AMs, and thus cannot totally account for the significant 
depletion observed. In contrast, some investigators showed no apoptotic events of AMs 
during influenza infections in pigs [262]. I believe that this significant AM depletion 
during sublethal influenza infections might have resulted from changes in their key 
survival signals in the lung microenvironment. These survival signals are probably 
altered and/or reduced by the damage and death of influenza-infected epithelial cells. To 
address this possibility, cross-talk between resident AMs and respiratory epithelial cells 
needs to be explored carefully and tested for major alterations during influenza 
infections. In addition, it is critical to determine the type of resident AM cell death in 
vivo during influenza infection, which may elucidate signals causing this depletion 
process. Generally, there are several ways to determine the type of cell death, including 
microscopic examination of the morphological changes in the cellular structures to 
differentiate, for example, between apoptotic and non-apoptotic cell death events. Also, 
monitoring certain biochemical changes inside the cells may indicate the type of cell 
death. However, these methods may have some intrinsic technical limitations leading to 
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detecting cell death only under limited experimental settings. Also, some techniques may 
not be able to define the exact cell death type, as the detected features may overlap with 
various types of cell death [263, 264]. Therefore, several techniques with unrelated 
methodologic principles should be performed for better assessment of the type of cell 
death. 
 
 Different respiratory viral infections have been associated with secondary 
bacterial infections. Although we found significant depletion of the resident AMs during 
sublethal influenza infections using two different strains of H1N1 influenza A viruses as 
well as another influenza B virus strain, it will be essential to determine the impact of in 
vivo infections by other influenza A virus subtypes on lung-resident macrophages. In 
addition, it will be of paramount importance to test if other respiratory viruses, known to 
increase predisposition to SBP such as respiratory syncytial virus and parainfluenza 
viruses, can also induce resident AM depletion. If this novel mechanism is observed with 
different respiratory viruses, it will suggest AM depletion as a general mechanism for the 
increased respiratory viral-bacterial synergism. Thus, exploring new prophylactic and 
therapeutic interventions targeting this mechanism would be of great significance to 
reduce the global burden of SBP during seasonal influenza and any future influenza 
pandemics. In addition, testing different influenza virus strains for AM depletion ability 
may infer novel features contributing to viral infection outcomes away from the classical 
viral virulence determinants.  
 
 Another serious clinical aspect associated with influenza infections is the 
increased risk for airway hyperresponsiveness and asthma exacerbation. Therefore, 
establishing animal models of influenza infections concomitant with acute or chronic 
asthma pathogenesis may reveal novel interactions elicited by the loss of lung 
immunosuppressive state during resident AM depletion. 
 
 
Treatment Strategies of Secondary Bacterial Pneumonia Following Influenza  
 
 Acute lower respiratory tract infections represent a major public health problem 
causing significant clinical and socioeconomic burdens worldwide. Compared to other 
serious infections, they are the leading cause of morbidity and mortality in the United 
States [120]. Pneumonia is caused by the infection of the alveolar airspace, associated 
with accumulation of inflammatory cells and secretions in the alveoli causing acute 
inflammatory lung injury and impaired gas exchange. Treatment of this serious medical 
problem has been challenging. Despite the wide use of antibiotics since the advent of 
penicillin to the clinical use in 1940s, the significant mortality rates of influenza and 
pneumonia patients have persisted with minor changes for more than 50 years [119, 120]. 
Many patients progress from uncomplicated respiratory viral infections to severe 
complicated pneumonia with a high case fatality rate despite adequate antibiotic use, such 
as patients with SBP following influenza [212]. A recent example of this treatment failure 
was evident during the 2009 H1N1 influenza pandemic, in which about one third of the 
severe or fatal cases were complicated by SBP [35]. Therefore, in addition to new 
antibiotic classes, we definitely need a non-antibiotic approach for the effective 
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management of pneumonia. This will require a better understanding of lung 
immunopathology and the poor outcomes during antibiotic treatment of pneumonic 
patients. 
 
 One of the enduring questions in this field has been whether adjunctive 
corticosteroid treatment of pneumonia can improve the outcomes. [227, 239]. The answer 
to this question has been perplexed by the mixed results shown in several clinical studies 
of adjunctive corticosteroid use for treating pneumonia in humans [220, 221, 223, 224, 
240-242]. Some of these clinical trials showed beneficial effects, while others showed 
detrimental or no effect after combining corticosteroids with the standard antibiotic 
treatment of pneumonia. 
 
 Using a well-established mouse model of SBP following influenza infection, we 
tested the hypothesis that adjunctive corticosteroid therapy can modulate antibiotic-
induced immunopathology during treatment of severe cases of SBP. We also tested the 
impact of early corticosteroid treatment on primary influenza infection and the outcomes 
of ampicillin treatment of SBP under these settings. We could monitor the progression of 
SBP in vivo using bioluminescence imaging, which is a non-invasive accurate surrogate 
measure of the pneumococcal burden in the lungs. Thus, prior to antibiotic treatment, we 
classified the pneumonic mice into groups with mild or severe SBP based on the 
pulmonary bacterial burden. 
 
 First, we found an interesting direct correlation between the pneumococcal 
burdens in the lungs at the onset of ampicillin treatment and the treatment outcomes. 
Larger bacterial burdens generated more inflammation upon ampicillin-mediated 
bacterial cell lysis. The release of copious amounts of bacterial PAMPs aggravated the 
ongoing inflammatory responses in the lungs by activating the inflammatory signaling 
pathways of different PRRs, including TLR2 detecting pneumococcal cell wall fragments 
[204]. Thus, the increased lung immunopathology associated with antibiotic treatment of 
mice with severe SBP eventually caused higher mortality.  
 
Additionally, adjunctive dexamethasone therapy could significantly rescue severe 
cases of SBP after dampening ampicillin treatment-induced inflammation in the lungs 
and improving pulmonary vascular permeability. However, it worsened the morbidity of 
mice with mild SBP reflected by delayed recovery of their body weight.  
 
 On the other hand, the early start of dexamethasone therapy during influenza 
infection resulted in loss of its protective functions. Corticosteroids do not only display 
potent anti-inflammatory activities, but can also cause systemic immunosuppression 
[219, 235]. We examined if early dexamethasone therapy had detrimental impact on the 
adaptive immunity against primary influenza infection. Indeed, early dexamethasone 
treatment significantly reduced numbers of CD8
+
 and CD4
+
 T cells in the lungs on day 7 
after influenza infection. This was associated with delayed influenza viral clearance and 
consequently increasing viral-mediated lung damage, which was implied by the 
accelerated body weight loss before secondary pneumococcal challenge. 
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 We also tested the efficacy of DABA, a novel immunomodulator that was shown 
to attenuate endotoxin-induced acute lung injury [230]. Combined DABA therapy with 
ampicillin treatment of SBP demonstrated protective effect similar to that of 
dexamethasone. However, it did not have a negative effect on the morbidity of mice with 
mild SBP after either adjunctive or early DABA treatment regimen. Nonetheless, its early 
administration during influenza infection was associated with partial loss of its protective 
functions.  
 
 
Insights 
 
 Our findings highlighted several important aspects about the efficacy of 
adjunctive corticosteroid therapy in CAP, which may give insights explaining part of the 
discrepancies in the clinical studies of corticosteroid use in CAP. The first aspect is the 
impact of the severity of pneumonia and the bacterial load size in the lungs at the onset of 
antibiotic treatment on the adjunctive therapy outcomes. Indeed, the differential treatment 
outcomes in our murine model of SBP are consistent with several randomized controlled 
clinical trials that demonstrated positive outcomes of adjunctive corticosteroid therapy 
only in the severe cases of CAP in humans [220, 221, 241, 242]. However, the criterion 
that we used for defining the severity in our murine model of SBP relies on the bacterial 
burden in the lungs, different from the clinical criteria for severe CAP in humans, which 
depend mostly on the lung functions. 
 
 Another critical aspect is the timing of dexamethasone therapy. Our experiments 
suggested that early dexamethasone treatment during the respiratory viral infections, such 
as influenza, would be associated with detrimental outcomes due to its suppressive 
effects on the anti-viral adaptive immunity. This aspect would be of paramount 
importance in patients with CAP that have simultaneous viral and bacterial etiologies. 
Therefore, we propose that the best treatment outcomes can be achieved if 
dexamethasone is administered during the resolution phase of the primary viral infection 
in conjunction with antibiotic treatment of the complicating bacterial pathogen. Taken 
together, adjunctive corticosteroid therapy can be used with great efficacy in the severe 
cases of CAP with careful consideration of the timing of treatment and the onset of any 
suspected primary viral infection. These findings will be interesting to the translational 
researchers, clinicians, and public health officials for better therapeutic management of 
lower respiratory tract infections.  
 
 
Future Directions 
 
 Our findings showed that the murine model of SBP can be used as a good 
surrogate for preliminary studies on novel immunomodulation approaches during 
antibiotic treatment of CAP. This model showed results that were clinically relevant to 
the randomized clinical trials of adjunctive corticosteroid therapy of CAP in humans. 
Moreover, in vivo bioluminescence imaging proved to be an accurate powerful tool for 
monitoring the bacterial outgrowth as well as the bacterial clearance in the lungs after 
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antibiotic treatment, which was also showed in several previous studies [202, 204, 265, 
266]. Therefore, our murine model of SBP and the powerful bioluminescence imaging 
tool would form a very useful technical approach for objective evaluation of the efficacy 
of novel prophylactic and therapeutic interventions for treating SBP following influenza. 
 
 Indeed, we started exploring novel immunomodulators that can be used for either 
preventing the increased lung immunopathology elicited during antibiotic treatment of 
SBP, or promoting the lung tissue repair processes. DABA is a novel immunomodulator 
that could improve survival of antibiotic-treated mice with severe SBP when given as 
adjunctive therapy. Furthermore, it did not affect body weight recovery after treatment, 
which was a potential drawback of adjunctive dexamethasone treatment of mice with 
mild SBP. DHBA, the active form of DABA, has multiple activities, such as strong iron 
chelation and free radical scavenging. DHBA has also been shown to inhibit the activity 
of matrix metalloproteinase-2 (MMP-2), which may help ameliorate the lung tissue 
damage during pneumonia [267]. MMP-2 is a member of the matrix metalloproteinases 
(MMPs) that have diverse catalytic functions, mainly facilitating degradation of different 
components of the extracellular matrix required for tissue remodeling [268]. 
Interestingly, increased levels of some MMPs were strongly correlated with the clinical 
severity of CAP and were suggested to contribute to increased lung tissue destruction 
[269]. Therefore, the probable MMP-inhibitory functions of DABA may mediate its 
protective functions during treatment of severe SBP. However, further investigation is 
needed to determine the exact mechanism of action of DABA treatment. In addition, 
exploring other immunodulators is crucial to help prevent the antibiotic treatment failure 
in recuing severely pneumonic patients by suppressing the exuberant inflammatory 
responses in the lungs and/or promoting the lung tissue repair process. 
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